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Introduction: Obesity is a major risk factor for non-communicable diseases (NCD), a 
collective term given to type 2 diabetes (T2D), hypertension (HTN) and cardiovascular 
disease (CVD). Globally, NCDs are the leading cause of death. In recognition of this, 
untested remedies are flooding the market. Buchu water is one of these herbal 
remedies advertised as having antihypertensive properties. This water is a by-product 
of the extraction of the oil from the leaves of Agathosma. Buchu water is already freely 
available to the public.  
Aim: The aims of the present study were to test the effect of ingestion of Buchu water 
on i) the blood pressure (BP) of diet induced hypertensive as well as normotensive 
rats when given as pre-treatment; ii) HTN in rats when used as treatment; iii) 
endothelial function using aortic rings from control and hypertensive rats; iv) the 
expression and/or activation of signalling proteins involved in NO production in the 
endothelium (PKB/Akt, AMPK, eNOS); v) insulin sensitizing effects in cardiomyocytes 
prepared from insulin resistant rats to determine possible cardiovascular effects.  
Methodology: We utilized rat models of obesity induced HTN and diet-induced obesity 
(DIO). Male Wistar rats were rendered i) hypertensive by feeding a high fat diet (HFD) 
and ii) insulin resistant after being placed on a high caloric diet for 16 weeks. Half the 
animals were placed on Buchu water treatment (26% (v/v) Buchu water) for a period 
of 16 weeks. Blood pressure, urine output, water and food consumption were 
measured. The animals on the HFD were sacrificed and intraperitoneal fat weight 
determined, aortas used in aortic ring studies and blood collected for biochemical 
analyses. Animals in the DIO model were sacrificed after 16 weeks and 
cardiomyocytes prepared to determine insulin sensitivity. 
Results: The HFD caused increases in body weight, visceral adiposity and blood 
pressure. Chronic Buchu water treatment i) reduced body weight gain and visceral 
adiposity in the HFD animals; ii) affected leptin levels and components of the renin-
angiotensin-aldosterone system (RAAS); iii) it both prevented the development of HTN 
when given in conjunction with the HFD and restored BP when used as treatment 
while having no effect on the BP of the control animals; iv) it had no effect on 
endothelial function nor did it activate any signalling proteins involved in the synthesis 
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of NO in the endothelium that may be responsible for vasodilation in the arteries; v) it 
elevated basal myocardial glucose uptake which can be cardioprotective.  
Conclusion: Our present study was novel and demonstrated that Buchu water 
treatment exhibits similar properties to that of antihypertensive medication known as 
angiotensin-converting enzyme inhibitors. It acts on the whole body RAAS in a similar 
manner reducing both BP and weight gain. It also reduced metabolic aberrations 
(HTN, leptin, aldosterone) seen in animals on a HFD, partly through visceral fat 
remodelling. In addition Buchu water also elicits some cardioprotective properties. 
Thus we conclude that Buchu water is an alternative, cost effective and ready available 
means to treat HTN and is beneficial to one’s health. 
Key words: Obesity, hypertension, traditional medicine, antihypertensive, Buchu. 
  




Inleiding: Vetsug is een van die hoof risikofaktore vir nie-oordraagbare siektes (NCD), 
'n kollektiewe term vir tipe 2-diabetes (T2D), hoë bloeddruk (HTN) en kardiovaskulêre 
siektes (CVD). Wêreldwyd neem NCD toe en is die hoofoorsaak van sterftes. Na 
aanleiding hiervan, is daar tans ŉ oorstroming van natuurlike produkte wat 
geadverteer word as antihipertensiewe middels maar met geen wetenskaplike bewyse 
hiervan nie. Boegoewater is een van hierdie kruiemiddels wat  bestaan uit  die waterige 
byproduk van ekstraksie van boegoe-olie uit die blare van Agathosma. Boegoewater 
is reeds vrylik beskikbaar aan die publiek.  
Doelstellings: Die doelwitte van hierdie studie was om die effek van Boegoewater op 
i) die bloeddruk van hipertensiewe en kontrole rotte, beide voorkomend en as ii) 
behandeling; iii) endoteelfunksie van aortaringe; iv) die uitdrukking van proteiene 
betrokke by NO seintransduksie (PKB/Akt, AMPK, eNOS); v) insulien sensitisering 
van kardiomiosiete, te toets.  
Metodes: Ons het gebruik gemaak van twee rot modelle; i) wat vetsug veroorsaak met 
gepaardgaande hoë bloeddruk en ’n ander wat gepaardgaan met ii) dieet-
geïnduseerde vetsugtig (DIO) met insulienweerstandigheid. Manlike Wistar rotte was 
geklassifieer as i) hipertensief na inname 'n hoë vet dieet (HFD)  en as ii) insulien 
weerstandig na inname van 'n hoë kalorie dieet (DIO) vir 16 weke. Die helfte van  die 
diere is met Boegoewater behandel (26% (v / v) Boegoewater) vir 'n tydperk van 16 
weke. Gedurende die 16 weke van behandeling is die bloeddruk, urine, water- en 
voedselverbruik gemeet. Die diere op die HFD is na 16 weke opgeoffer en die 
liggaamsgewig en intraperitoneale vet gewig bepaal, die aorta ringe is geisoleer vir 
kontraksie/ontspannings studies en die bloed gekollekteer vir biochemiese analises. 
Die diere in die DIO model is ook na 16 weke geslag en kardiomiosiete is voorberei 
om die insuliensensitiwiteit te bepaal. 
Resultate: Die HFD het 'n toename in liggaamsgewig, viserale vet en bloeddruk 
teweeggebring. Kroniese Boegoewater behandeling het i) die liggaamsgewigtoename 
en viserale vet verlaag in die HFD diere; ii) leptienvlakke en komponente van die RAAS 
verlaag; iii) die ontwikkelling van hoë bloeddruk voorkom asook alreeds verhoogde 
bloeddruk effektief verlaag; iv) geen effek op endoteelfunksie of die uitdrukking van 
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proteiene geassoseerd met NO produksie, getoon nie; v) basale glukose opname van 
kardiomiosiete verbeter. 
Gevolgtrekkings: Ons huidige studie, die eerste van sy soort, het getoon dat 
Boegoewater behandeling die aanvang van HTN kan voorkom, asook hipertensie kan 
behandel .  
Die studie het aangetoon dat Boegoewater soortgelyke eienskappe as die 
angiotensien-omskakelingsensiem (ACE) inhibeerders besit aangesien dit 
komponente van die RAAS beïnvloed het, gewigstoename beperk het en bloeddruk 
verlaag het. Metaboliese veranderinge soos leptienverlaging word aan hermodelering 
van die vetdepots toegeskryf. Verder lei Boegoewater behandeling tot miokardiale 
beskerming.  
Dit het ook metaboliese afwykings (soos HTN en glukose onverdraagsaamheid) in 
individue op 'n HFD verminder deur deels viserale vet hermodellering. Bykomend aan 
al die einskappe het Boegoewater beskerming ontlok teen iskemie deur verbeterde 
glukose opname tydens basale vlakke in kardiomiosiete. Ons het daarin geslaag om 
te bewys dat Boegoewater 'n alternatiewe, koste-effektiewe en beskikbare middel is 
om HTN meer te behandel en dat dit voordelig is vir jou gesondheid. 
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CHAPTER 1: Literature Review 
1.1 Obesity 
Obesity is a major risk factor for non-communicable diseases (NCD), a collective term 
given to type 2 diabetes (T2D), hypertension (HTN) and cardiovascular disease 
(CVD). Non-communicable diseases are currently a global public health concern and 
the leading cause of death worldwide. The number of deaths caused by NCD each 
year is currently far greater than all the other diseases combined (Kelly, Narula, & 
Fuster, 2012; Murray et al., 2012). In 2008 it was estimated that 35% of adults aged 
25 years and older were overweight (BMI > 25kg/m2) and 12% of the world’s 
population was obese (BMI ≥ 30 kg/m2) (Stevens et al., 2012).Thus more than 1 billion 
adults are overweight and millions are obese (Deitel, 2003). Obesity is therefore not 
just a disease of developed nations, but also from developing countries. Obesity levels 
in certain lower-income and transitional countries are as high as or higher than those 
reported for the United States and other developed countries. Moreover, these levels 
are shown to be constantly on the increase. In the US alone it is estimated that one 
third of the population over the age of 20 years is obese (27.3% of men and 33.2% of 
women) (Hedley et al., 2004). Even in South Africa we have not been spared the 
widespread increase of obesity. The first South African Democratic Health Survey 
(SADHS), undertaken in 1998 and published in 2002 reported that the prevalence of 
overweight (Body Mass Index (BMI) > 25) and obesity (BMI > 30) in South Africa was 
more than 29% for men and 56% for women (T. Puoane et al., 2002). It is clear that 
obesity is currently one of the biggest global health problems and that the number of 
obese or overweight individuals continue to rise worldwide (Seidell, 2000). A severe 
disease such as obesity, which is characterized by a pathological increase in body 
weight, can result in HTN, hyperinsulinaemia, insulin resistance, diabetes and 
dyslipidaemia, all of which are factors independently associated with an increased risk 
of CVD (Brands et al., 1995; Hall, 1993; Hall, 2000; Hall, Hildebrandt, & Kuo, 2001; 
Hall, 2003). 
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Both HTN and obesity have therefore been identified as major risk factors for the 
development of vascular dysfunction and cardiac complications which are associated 
with an increase in mortality worldwide (Hubert et al., 2012; S. S. Lim et al., 2012; 
Murray et al., 2012). 
 
1.1.1 Concept of Obesity 
Obesity refers to the excess storage of energy in the form of fat cells, also known as 
adipose tissue (Mikhail, Golub, & Tuck, 1999). When energy intake exceeds 
expenditure, fat cells enlarge or increase in numbers thereby increasing the storage 
capacity (Simonds & Cowley, 2013). There should therefore be a tight regulation of 
caloric intake and energy expenditure to maintain a balanced energy homeostasis.  
Although obesity is linked to mortality, it is not the accumulation of excess body fat 
that is the direct cause of death but rather an increase of a variety of associated 
diseases that can cause death and disability. One of the serious comorbid diseases 
of obesity is HTN or elevated blood pressure (BP) (Simonds & Cowley, 2013). It seems 
clear that obesity causes HTN rather than the reverse, because losing weight lowers 
BP, whereas lowering BP does not correct obesity (Goodfriend, 2008). Over eating 
contributes to both obesity and HTN since the sodium raises BP and the calories 
increase weight (Morse, Zhang, Thakur, & Reisin, 2005). 
The presence of HTN increases the risk for the development of CVDs including heart 
disease and renal failure (Simonds & Cowley, 2013). 
There are many sophisticated anthropometric techniques to measure and assess the 
degree of Obesity. The three most common methods are i) the Body Mass Index (BMI) 
also referred to as the Quetelet’s index, ii) the waist-to-hip ratio (WHR) and iii) waist 
circumference. All three techniques calculate the % body fat (Dalton et al., 2003). They 
are all measured by using anthropometric tools. 
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1.1.2  Definitions of obesity: 
1.1.2.1 Body mass index (BMI) 
The BMI technique relates weight to height and is the most widely used technique to 
calculate the degree of obesity. BMI gives a good estimate of the prevalence of obesity 
within a population. It is calculated by dividing an individual’s body weight (kg) by their 
height (m) squared (weight (kg)/height (m2)). Below in Table 1-1 it illustrates all the 
various ranges of BMI and how they are classified into different categories.  
Table 1-1: BMI Classification. 
BMI range Category 
less than 16.5 Severely underweight 
from 16.5 to 18.5 underweight 
from 18.5 to 25 normal 
from 25 to 30 overweight 
from 30 to 35 obese 
from 35 to 40 clinically obese 
above 40 dangerously obese 
 
It is known that a high BMI has consistently been associated with various health 
complications as well as an increased risk of developing CVD, HTN, dyslipidaemia, 
insulin resistance or T2D (Field et al., 2001) . Many health problems in the world focus 
on the high prevalence of obesity and high BMI, however it is easy to forget that being 
underweight also carries health risk, therefore some focus must also go towards 
having a too low BMI. There are many causes for being underweight, the condition 
clearly suggest that your body is not obtaining all the essential nutrients to function 
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properly. Having a BMI below 18.5 is associated with health risks such as bone loss, 
decreased immune function, cardiac problems (iron-deficiency) and infertility. 
A BMI value that exceeds 25 is classified as overweight. Whereas obesity is defined 
as a BMI greater than 30 and morbidly obese if an individual’s BMI exceeds 35 
(Obesity: Preventing and Managing the Global Epidemic. Report of a WHO 
Consultation.2000; Deitel, 2003). 
 
1.1.2.2 Waist-to-hip ratio (WHR) 
A more precise method used to determine the severity of obesity is the WHR. This is 
the preferred method, since it gives a better indication of obesity compared to BMI. 
This is due to the fact that it is more directly proportional to the abdominal obesity and 
the amount of metabolic active visceral fat than the BMI. The BMI rather gives an 
overall indication of the severity of obesity. Distribution of weight gain is an important 
factor when looking at obesity. Abdominal obesity is clinically diagnosed by a WHR 
that is greater than 0.95 in men and greater than 0.85 in women (Obesity: Preventing 
and Managing the Global Epidemic. Report of a WHO Consultation.2000). 
 
1.1.2.3 Waist Circumference 
Another simple and practical anthropometric technique used to determine the body fat 
or the prevalence of obesity, is the waist circumference (Dalton et al., 2003). This 
method is widely used, but is subject to measurement error. Circumference cut-off 
points for adults with increased health risks are: men ≥ 94 cm and women ≥ 80 cm. 
Whereas men with a waist circumference ≥ 102 cm and women ≥ 88 cm have an even 
greater risk of health problems (Lean, Han, & Morrison, 1995). 
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1.2  Fat stores  
Over the years, fat stores or adipose tissue have simply been seen as a way of storing 
additional energy to utilize later, if the need arises to keep the body powered or going. 
In recent years it has been discovered that this is not strictly true. In reality, adipose 
tissue plays a more complex role in a wide variety of interactions. Not only does it 
provide us with energy, but it is also involved in numerous hormonal, inflammatory and 
metabolic pathways (Seidell, 2000; Trayhurn & Wood, 2005).  
Adipose tissue consists of adipocytes and their main function is to store energy in the 
form of triglyceride (TG). Adipocytes store lipids in one of two ways: firstly by 
synthesizing it from products of glycolysis and secondly via the uptake of free fatty 
acids (FFA). Lipolysis is the mobilization of lipids, a tightly controlled process which is 
regulated by a hormone called insulin. Insulin is secreted from the beta cells which are 
situated in the pancreas (Engeli et al., 2003). Under the tight regulation of insulin, the 
adipocytes take up FFAs from the blood and store them in the form of intracellular lipid 
droplets. Adipose tissue stores can be found subcutaneously (SAT) or as visceral 
depots (VAT), in organ capsules and dispersed in close proximity to blood vessels and 
lymph nodes (Engeli et al., 2003). 
As an individual gains weight, there is an increase in adipose tissue mass. The 
increased adipose tissue mass results from increased adipocyte number (hyperplasia) 
and/or volume (hypertrophy) (Faust et al., 1978). Eventually the point is reached when 
the adipose tissue is unable to store surplus lipids in the form of TG. This prolonged 
period of nutrient overload causes the lipids to be deposited ectopically in non-adipose 
tissue such as the liver, pancreas and heart (Virtue & Vidal-Puig, 2010). This results 
in a toxic environment which can lead to insulin resistance and apoptosis in the cells 
(hepatocytes, beta cells, cardiomyocytes and skeletal muscle) where ectopic 
accumulation of lipids occurred. It is therefore essential for adipose tissue to be able 
to expand to maintain a healthy structure. 
Insulin sensitivity is reduced as a result of the state of demand to store excess 
nutrients, which leads to adipose tissue to become dysfunctional and inflamed. The 
low grade inflammatory state in which the adipose tissue is found in obesity is 
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associated with the production of pro-inflammatory cytokines from the immune system 
such as macrophages. Pro-inflammatory cytokines impair insulin sensitivity 
throughout the body via activation of c-Jun NH2-terminal kinase (JNK) and nuclear 
factor-kappa beta (NFKB) signalling pathways (Hirosumi et al., 2002; Cai et al., 2005). 
Large adipocytes also secrete macrophage-attracting chemokines which promote 
macrophage activation, recruitment and infiltration (Kim et al., 2007). The pro-
inflammatory macrophages cause a decrease in the formation of new small healthy 
adipocytes by releasing cytokines, increasing the number of large insulin resistant 
adipocytes (Lacasa et al,. 2007). This causes a vicious cycle where more chemokines 
and FFA is secreted, thus more macrophage activation leads to the formation of more 
large insulin resistant adipocytes. The balance between lipolysis and adipogenesis 
changes when one reduce insulin sensitivity and this leads to increased plasma FFA 
levels. This in turn, can increase the risk of developing T2D.  
 
1.2.1 Fat distribution in Obesity (pear and apple shape) 
To classify the pattern of weight gain is very important. The distributions of body fat in 
obese individuals give rise to many metabolic disturbances. Obesity can be classified 
as either abdominal obesity or lower body obesity. The association between “Android” 
(abdominal obesity or central obesity or upper body obesity) and CVD and diabetes 
rather than the more peripheral “gynaecoid” obesity (or lower body obesity with fat 
around the hips and buttocks) was first pointed out by Vague (1953). (Vague, 1953). 
Abdominal obesity has been shown by many studies to be more related to CVD and 
death than lower body obesity (Mikhail et al., 1999). The distribution of weight gain is 
different between males and females. Generally, men tend to deposit fat in the 
abdominal area giving rise to an “apple” shape, whereas women tend to deposit fat in 
gluteal and femoral regions resulting in a “pear” shape (Ashwell, Cole, & Dixon, 1985). 
“Pears” seem to have less intra-abdominal fat than “apples. Therefore men tend to be 
more at risk for CVD than women.  
In obesity, fat accumulation in the abdomen or VAT are more tightly correlated with 
development of HTN than SAT or below the pelvic brim adipose tissue, so more focus 
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should be placed on abdominal fat in scenarios where obesity associated HTN is the 
issue (Sironi et al., 2004). 
 
1.3 Hypertension 
Hypertension (HTN) is a term used to describe high BP (‘chronically elevated BP in 
the arteries’).  As the heart pumps blood to circulate through the body it exerts a force 
against the walls of the arteries. This is defined as BP. Blood pressure readings consist 
of two numbers or values, one over the other. The top one indicates the systolic blood 
pressure (SBP) and the bottom one the diastolic blood pressure (DBP). One or both 
of these numbers can be elevated in the development of HTN. 
Hypertension, which is a common condition worldwide, is diagnosed when systolic 
blood pressure (SBP) is constantly registered ≥140 mmHg and/or a diastolic blood 
pressure (DBP) ≥90 mmHg and/or taking antihypertensive medication (Burt et al., 
1995; Chobanian et al., 2003). 
Hypertension can be classified as essential (or primary) HTN or secondary HTN 
(Bokarev & Matvienko, 2013). Primary HTN has no identifiable cause but is rather the 
consequences of the interaction between environmental and genetic factors 
throughout one’s life. Conversely, secondary HTN can be recognized by having an 
identified cause. The pathological development of secondary HTN is often one of the 
following; thyroid dysfunction, aldosteronism, coarctation of the aorta and renal 
parenchymal disease (Viera & Neutze, 2010). Secondary HTN is a treatable or curable 
condition, because in most cases the HTN can be treated by e.g. undergoing surgery 
or be managed by medications (Akpunonu, Mulrow, & Hoffman, 1996). Some journals 
refer to secondary HTN as “surgical hypertension”. Most patients have primary HTN 
and this account for 95% of known cases, whereas the remaining 5% will have 
secondary HTN. 
Hypertension is often associated with obesity since most obese individuals suffer from 
high BP and some of them even tend to develop left ventricular hypertrophy (LVH). 
Left ventricular hypertrophy develops in response to high BP and volume overload 
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(Gardin & Lauer, 2004). This implies that the left ventricle, the main heart chamber 
that does the most work to pump the blood to circulate through our body, is required 
to work harder. As the workload increases, the thickness of the chamber walls 
increase and some of the elasticity is lost. Eventually the hearts fail to pump the blood 
in the circulation with sufficient force. This condition is common in obese patients with 
high BP. 
Hypertension or high BP is also a very important public health challenge globally. It is 
estimated to be the number one risk factor for CVD (S. S. Lim et al., 2012). CVD 
caused 17 million deaths in 2008 and is still increasing every year (Kelly et al., 2012). 
In 2005 Kearney et al. conducted a study regarding the burden of HTN on the world. 
They estimated that the absolute value of HTN on the adult population globally in 2000 
was 26.4%. Furthermore, they predicted that in the next 25 years this number would 
significantly increase by about 60%, resulting in a total of 1.56 billion affected cases 
worldwide. (Kearney et al., 2005). Subsequently, in 2008 the overall global prevalence 
of raised BP levels in adults over the age of 25 years was 40% (1040 million) (Danaei 
et al., 2011). In the African region the incidence of raised BP was the highest (46%) in 
the world for both sexes combined. The lowest prevalence region was the Americas 
with a rate of 35%. The occurrence of HTN has therefore been reported in various 
regions throughout the world and is on the increase in both low as well as high income 
countries. 
Importantly, HTN is not only an international concern, but also affects us locally. After 
the first democratic elections in 1994, the Department of Health conducted the first 
South African Demographic and Health Survey (SADHS) in 1998. This SADHS 
revealed that 21% of the adult population in South Africa suffer from HTN (Steyn et 
al., 2001), which is equivalent to other industrialized populations, according to the 
World Health Organisation (WHO) guidelines on HTN (Burt et al., 1995). Today HTN 
is more common amongst obese individuals than amongst the lean (Steyn et al., 
2001). This is a major risk factor leading to an increased risk for heart attacks, strokes, 
myocardial infarction, end stage-renal disease (ESRD), congestive heart failure, LVH, 
blindness and peripheral vascular disease (Fiebach et al., 1989; MacMahon et al., 
1990; Whelton et al,. 1992; Whelton, 1994; Stamler, Stamler, & Neaton, 1993). 
Patients who suffer from HTN are usually unaware that they have this condition unless 
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their BP has been measured at a local or mobile clinic, by their doctor (GP), the 
hospital, or simply when they donate blood. The risk of developing CVDs is 
significantly increased by the presence of HTN (O'Donnell et al., 1997). 
Cardiovascular disease does not only cause significant morbidity, but also imposes 
high healthcare cost and is currently the number one cause of death globally (Go et 
al., 2013; Roger et al., 2012). 
Systolic blood pressure is a stronger risk factor for cardiovascular and renal disease 
than the corresponding relationship for DBP (Izzo, Levy, & Black, 2000). In knowing 
this, there is more focus on SBP in the clinical setting than DBP. Hypertension is only 
one of several proven major risk factors for CVD. In combination, these factors provide 
a strong basis for predicting the risk of cardiovascular complications in general. 
 
1.3.1 Effect of age on BP 
There is a constant age-related increase in BP and this is a typical occurrence in most, 
but not all populations (Kannel, 1996). Hypertension increases with age, in such a 
manner that more than one out of every four adults in South Africa older than 60 years 
of age suffer from HTN (Steyn et al., 2001). With age, blood vessels become less 
elastic which is one of the causes of BP increases with age. 
 
1.3.2 Effect of race on BP 
In South Africa, HTN occurs in all races; white, black, coloureds, and Indian 
communities. However the effects of chronic HTN are different in these populations 
(Steyn et al., 2001). Seedat et al. (1999) summarised that black hypertensive patients 
in South Africa may suffer from cerebral haemorrhage and kidney disease which can 
lead to uraemia. Coronary heart disease (CHD) was previously thought to be relatively 
uncommon in the black population. However, a recent study conducted by Tibazarwa 
et al. (2009) among the black population of Soweto suggested that, contrary to popular 
belief, CHD is on the increase in this population group (Tibazarwa et al., 2009). 
Coronary heart disease remains a major outcome in white and Indian communities 
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(Seedat, 1999). There is no known association between ethnicity and the risk of 
developing HTN. An individuals’ risk for developing HTN is therefore more dependent 
on their socioeconomic status than their ethical background (Opie & Seedat, 2005). 
Increasing urbanization leads to a change in lifestyle (high fat diet, inactivity, obesity). 
As a result, the responsiveness of antihypertensive medication such as beta-blockers 
and angiotensin-converting enzyme inhibitors was found to be poor in black patients 
unless combined with diuretics.  Alternatively, vasodilators or calcium channel 
blockers responded best to act against high BP in hypertensive black patients (Seedat, 
1999).  
 
1.4 Regulation of BP 
The body is in constant homeostasis, a state of equilibrium where it is maintaining a 
‘constant’ state despite changing conditions. This is achieved when the body responds 
to external change in a physiological manner to keep the body functioning. The body 
functions as a whole through various mechanisms of communication between different 
cell types, whether it is accomplished through direct signalling, synaptic, endocrine or 
paracrine messengers (P. D. Wilson, Du, & Norman, 1993). Some of the major factors 
that can affect the regulation of BP are the contractility of the heart, blood volume, 
peripheral resistance, viscosity of the blood and vascular tone. The greater the blood 
volume in the body, the higher the rate of return of blood to the heart. This increases 
the work load on the heart, which results in an overall increase in cardiac output 
(Patterson, Piper, & Starling, 1914). The blood volume in the body is regulated by a 
steadfast process that involves the liver, kidneys and arteries. Here, Na+ as well as 
the viscosity or thickness of the blood plays an important role regarding BP. The thicker 
the blood is, the greater the arterial pressure (Letcher, Chien, Pickering, Sealey, & 
Laragh, 1981). Red blood cells (RBC) are responsible for this viscosity. When an 
individual’s RBC count increases and becomes too high, may result in Phlebotomy. 
This is a common treatment for high blood viscosity. This simple procedure involves 
the removal of some blood from a patient’s blood stream. A small incision in a vein is 
used to control how much blood is removed in order to control and lower the RBC 
count. On the other hand, if an individual develops a RBC count that is too low, he/she 
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is at risk of developing anaemia. Blood vessels play an important role in the 
management of vascular tone and resistance in the circulatory system. Vascular tone 
is regulated by vasoconstrictors and vasodilators respectively. Vasoconstrictors such 
as phenylephrine (PE) constrict the blood vessels which lead to a decrease in the 
radius of the arteries (Franco et al., 2001). The opposite happens with vasodilators 
(Furchgott & Zawadzki, 1980). By reducing the diameter of the arteries, the body’s BP 
increases. With obesity, there is a build-up of FFA in the blood vessel which reduces 
the free flow of blood and therefore elevates the resistance within the arteries. The 
body regulates BP and flow via three mechanisms:  i) auto-regulation, ii) neural 
regulation and iii) endocrine regulation (Bayliss, 1902; Hall et al., 2003). Each 
mechanism acts in a distinctive way to keep the BP constant, so that the body can 
function in a state of homeostasis. These regulatory mechanisms can be divided into 
short term mechanisms, which regulate blood vessel diameter, heart rate and 
contractility; as well as long-term mechanisms which regulate blood volume. 
 
1.5 The role of the Renin Angiotensin Aldosterone System (RAAS) in 
Hypertension 
The Renin Angiotensin Aldosterone System (RAAS) plays a critical role in maintaining 
constant homeostasis with regards to arterial pressure, tissue perfusion, electrolyte 
levels and body fluid volume (blood) (Atlas, 2007). 
 
1.5.1 Renin –Production & Functional role 
The biosynthesis of renin occurs in specialized granular cells of the juxtaglomerular 
(JG) apparatus in the kidneys. This is where the renin angiotensinogen aldosterone 
hormonal cascade originates. Renin is synthesised as preprorenin and rapidly 
processed to prorenin (Pratt, Carleton, Richie, Heusser, & Dzau, 1987). The activation 
of renin occurs during the removal of a prosegment of the renin peptide through a 
proteolytic split from the N-terminus, leaving mature renin behind. Mature renin (also 
active renin) is stored in the JG apparatus in granules. These granules release renin 
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into the systemic circulation by an exocytotic process. The three stimuli that cause 
these granules to release renin into the circulation are: i) a reduction in arterial 
pressure detected by baroreceptors in the body (e.g. blood volume loss/decrease), ii) 
reduction of sodium chloride levels and iii) sympathetic nervous system (SNS) activity 
where norepinephrine acts through beta1-receptors on the JG apparatus (Skinner, MC 
Cubbin, & Page, 1963; Skinner, MC Cubbin, & Page, 1964). The latter two pathways 
mentioned operate slower than the first (Brown, 2006). Other tissues, including the 
brain, adrenal gland, visceral adipose tissue and vascular tissue, also synthesize renin 
but the possible actions of renin in these tissues are poorly understood (Atlas, 2007). 
Since renin regulates the initial, rate limiting step of RAAS the secretion of renin is a 
key determinant of this cascade. Renin sets the RAAS in motion with the cleaving of 
a peptide bond on angiotensinogen, creating angiotensin I (Ang I). The primary site 
for the synthesis of renal angiotensinogen is in the liver. Here the liver continuously 
produce angiotensinogen and release it into the blood after synthesis. It is an alpha2-
globulin peptide which is the main substrate for the circulating enzyme, renin (Di 
Raimondo et al., 2012). 
 
1.5.2 Angiotensinogen –Functional role  
As mentioned earlier, Ang I is formed when renin cleaves angiotensinogen. Ang I has 
no known physiologically relevant role and serves only as a precursor to Angiotensin 
II (Ang II). Angiotensin I, an inactive decapeptide, is hydrolysed by angiotensin-
converting enzyme (ACE) to form Ang II. Angiotensin-converting enzyme is mainly 
involved in enzymatic reactions which result in decreased vasodilation and increased 
vasoconstriction (Carey & Siragy, 2003). Angiotensin-converting enzyme is a target 
for ACE inhibitors which will decrease the production of Ang II. Angiotensin-converting 
enzyme inhibitors are one of the major antihypertensive classes of drugs used in the 
treatment of HTN. After the cleavage of Ang I this process leaves Ang II behind, an 
octapeptide. Angiotensin II is biologically active, unlike Ang I, and a potent 
vasoconstrictor which can be found in vascular endothelial cells to control BP. 
Angiotensin II is the primary active product of the renin angiotensin aldosterone 
cascade and acts through receptors called angiotensin type 1 (AT1) and angiotensin 
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type 2 (AT2) receptors (Carey, Wang, & Siragy, 1999). Signalling through AT1 
receptors is responsible for protein phosphorylation, cell proliferation, vasoconstriction 
and antidiuresis or antinatriuresis, whereas signalling through the AT2 receptors is 
responsible for completely opposite effects such as protein dephosphorylation, 
antiproliferation, vasodilation and diuresis. These opposing processes play a 
protective role in the regulation of BP.   
Angiotensin II is therefore  responsible for  the regulation of AT1 and AT2 receptors 
(Carey, Wang, & Siragy, 2000), which maintains BP through the regulation of 
contraction of smooth muscle cells in the blood vessels playing an important role in 
vasodilation. Ichiki et al,. (2013) reported that mice lacking the genes to encode for 
AT2 receptors have higher levels of BP compared to wild-type controls. Angiotensin II 
also stimulates and regulates the synthesis and release of aldosterone (ALD) via AT1 
receptors located on the zona glomerulosa, the outer most zone of the adrenal cortex 
in the adrenal gland were it is produced. 
 
1.5.3 Aldosterone –Functional role 
Recently, ALD has been described as having a key role in the relationship between 
obesity and HTN. Aldosterone is the primary salt-retaining hormone in the body. It is 
a steroid hormone (part of the mineralocorticoid family) and has a molecular weight of 
360.4 Daltons (Laragh & Stoerk, 1957). It is produced and secreted by the glomerulosa 
zone in the adrenal gland and is responsible for controlling and regulating 
hydromineral metabolism (Rajagopalan & Pitt, 2001).  
The target organ for ALD in the body is the kidney. In the distal part of the nephron, 
ALD encourages reabsorption of Na+ and Cl- ions and the secretion of K+ and H+ ions 
in the blood vessel lumen. Consequently, there is an increase in extra-cellular 
osmolarity and water retention. The water retention increases the blood volume and 
therefore the BP. Regulation of ALD secretion is linked to the body’s  water balance 
and brings three factors into play (Smeaton, Andersen, & Fulton, 1977). These are i) 
the RAAS (discussed earlier), ii) the plasmic Na+/K+ ratio and iii) adrenocorticotropic 
hormone (ACTH). Physiologically there seems to be a circadian rhythm involved in the 
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regulation of the levels of ALD in the blood, which may be linked to changes in body 
posture (Lamarre-Cliche et al., 2005). Levels of ALD have been found to be higher in 
children than in adults, and it also increases during pregnancy (Elsheikh et al., 2001; 
Smeaton et al., 1977). In summary, ALD is a major role player in regulating the sodium 
and potassium balance in the body and thus regulates extracellular volume. It also 
controls BP by enhancing the reabsorption of sodium and water. By doing this it can 
increase BP if needed. 
In pathology, high levels of ALD or hyperaldosteronism is caused by the over-
production of ALD by the adrenal glands in the body. This causes a reduction in 
potassium in the blood which is known as hypokalaemia (Calhoun, Nishizaka, Zaman, 
Thakkar, & Weissmann, 2002). Conversely, if there are low levels of ALD there will be 
less reabsorption of the Na+ and Cl- ions and less secretion of K+ and H+ ions.  
It is clear that ALD controls the sodium and potassium balance in the body. The more 
potassium we consume the more sodium is excreted through the urine and out of the 
body. Potassium also helps to relax smooth muscles in the walls of blood vessels 
which lower BP (Nielsen-Kudsk, 1996). The opposite is true for sodium. Sodium 
activates the sodium channels on smooth muscle cells and induces contraction, 
mediated by Ca2+ influx (Shinjoh, Nakaki, Otsuka, Sasakawa, & Kato, 1991). 
In obese individuals the excess adipose tissue secretes FFA into the circulation 
resulting in a release of hepatic factor from the liver, which in turn increases the 
synthesis of serum ALD (Goodfriend, 2008). Reports also suggest that there is a link 
between the BMI in humans and the plasma Ang II levels, plasma renin activity (PRA) 
and plasma ACE (El-Atat, Aneja, Mcfarlane, & Sowers, 2003).  
When components of the tissue RAAS or circulation RAAS are inhibited or 
overexpressed it can lead to a disturbance in the body and thus the occurrences of 
pathophysiological processes. 
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1.5.4 RAAS and CVD 
It has been proposed that abnormal activity of the RAAS can lead to the pathogenesis 
of CVD and HTN (Di Raimondo et al., 2012). During normal physiological conditions 
the function of cardiac RAAS is to maintain cellular balance by inhibiting or inducing 
cell growth. It also plays a role in cell proliferation as well as mediating an adaptive 
response to myocardial stretch. We can assume that RAAS also influences vascular 
function because mineral corticoid receptors are expressed in vascular endothelial and 
smooth muscle cells as well in cardiomyocytes, a key role player in CVD is 
atherosclerosis (Rajagopalan, Duquaine, King, Pitt, & Patel, 2002). 
 
1.5.5 RAAS and Hypertension 
The onset of HTN is often a result of the dysregulation of RAAS in the body. Secondary 
HTN is the most common form of dysregulation of RAAS. With essential HTN, most 
young individuals have moderate to mild increases in plasma renin activity (Degli 
Esposti et al., 1979). This can be due to various mechanisms; one being the over-
activity by the SNS. In the older population as well as women and type 2 diabetics, 
HTN with low levels of plasma renin activity are reported (Alderman, Cohen, Sealey, 
& Laragh, 2004; Messerli et al., 1983). 
 
1.5.6 RAAS and Obesity 
The RAAS has an important role in regulating BP as mentioned earlier and plays a 
part in the regulation in fluid and electrolyte balance. Obesity acts on the RAAS 
through three mechanisms; i) sympathetic stimulation ii) the synthesis of adipokines 
by excess visceral tissue and iii) hemodynamic alterations (de Kloet et al., 2013; 
Goodfriend, 2008; Trayhurn & Wood, 2005). High levels of ALD in obese individuals 
could have multiple causes, the expanding adipose tissue being one.  Adipose tissue 
also expresses the renin substrate angiotensinogen. The relationship between renin 
and angiotensinogen is such that the reaction never saturates. If the substrate 
increases, the levels of plasma renin increase. This upstream activity in turn, increases 
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the formation of Ang II and causes the downstream levels of ALD to be even higher. 
Angiotensin II acts via AT1 receptors located on the zona glomerulosa, the outer most 
zone of the adrenal cortex in the adrenal gland. There it stimulates the release and 
regulates the synthesis of ALD. Once aldosterone (ALD) is released into the blood 
stream, it results in sodium reabsorption and water retention thus increasing BP (Atlas 
et al., 1979; Rajagopalan & Pitt, 2001). Another cause of high levels of ALD in obese 
patients is the influence of inhibitors and stimuli on the adrenal cortex. The principal 
inhibitor is atrial natriuretic peptide (ANP). Obese patients have low levels of ANP, 
which may encourage ALD secretion (Wang et al., 2004). Natriuretic peptide clearance 
receptors (NPR-C) are abundant in adipose tissue suggesting that adipocytes help 
with the removal of ANP in the circulation (Sarzani et al., 1995; Sarzani et al., 1996). 
In obese individuals the amount of ALD in blood and urine is more elevated when 
compared to lean individuals (Goodfriend, 2008).  Aldosterone levels are found to be 
higher in patients with drug-resistant HTN and many of these patients are also obese. 
 
1.5.7 RAAS and vasculature dysfunction 
The uptake of circulating renin by vascular smooth muscle and endothelial cells 
generate Ang I and Ang II. Studies have suggested that the maintenance of 
cardiovascular homeostasis contributes to the effects of vascular RAAS by mediating 
its long term effects through AT1 and AT2 receptors (Kaschina & Unger, 2003). This 
remodels the vascular smooth muscle cells by stimulating proliferation. The 
dysfunction of the endothelium is associated with the upregulation of ACE. 
Angiotensin-converting enzyme has a dual function which disrupts the vasodilation via 
the degradation of bradykinin (a potent vasodilator) (Gainer, Morrow, Loveland, King, 
& Brown, 1998; Hornig, Kohler, & Drexler, 1997) and vasoconstriction of the 
surrounding tissues with the production of Ang II (Carey et al., 1999; Kaschina & 
Unger, 2003). High levels of ACE can lead to additional alterations such as 
inflammation and oxidative stress (Chabrashvili et al., 2003). Angiotensin II is known 
to boost the production of reactive oxygen species (such as superoxide and hydrogen 
peroxide), which has been associated with HTN, hypertrophy and inflammation 
(Reckelhoff & Romero, 2003). 
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1.6 The sympathetic nervous system (SNS) and its role in Hypertension 
The SNS contributes to the homeostatic balance of the body (Simonds & Cowley, 
2013). In obese individuals there are several mechanisms and mediators causing 
over-activity of the SNS leading to increased adrenergic sympathetic stimulation of the 
heart, vasculature and kidneys, increasing BP by elevating cardiac output, vascular 
resistance and fluid retention. Inhibiting the SNS produces the opposite effects (de 
Kloet et al., 2013). Most notable among all of these mechanisms are 
hyperinsulinaemia and increased plasma FFA (Hall et al., 2001). Increased 
sympathetic activity can be measured directly or indirectly in obese subjects. 
There are several mechanisms and mediators which may cause over-activity of the 
adrenergic system in obese individuals. In obese individuals, the amount of visceral 
fat load is usually more than in lean individuals and the amount of FFA is significantly 
higher than in non-obese individuals. This delivers a FFA load to the liver, which in 
turn activates hepatic afferent pathways and leads to the further activation of the SNS. 
High FFA levels are believed to raise BP either by stimulating the SNS or enhancing 
a vascular response, thus increasing BP (Hall et al., 2001). Long term effects of FFA 
on BP are less clear and further investigation is needed (Hall et al., 2001). A study 
showed that by infusing dogs with long chain fatty acids, there was no added effect 
relating to BP (Van Vliet, Hall, Mizelle, Montani, & Smith, 1995), but in contrast, 
infusion of long chain fatty acids to rats, demonstrated a rise in BP and increased heart 
rate (Grekin et al., 1997). At present, the relationship between FFA and BP or HTN is 
not clearly understood and needs more scientific investigation. 
 
1.7 Role of insulin in Hypertension 
In the past, insulin or hyperinsulinaemia was considered a key factor in the onset of 
obesity derived HTN (Hall et al., 2001). The reason for this was that obese subjects 
usually have elevated insulin levels, which they require to maintain adequate 
metabolism of all the excess glucose and FFA in their circulation. A study in 1989 by 
Hall et al. showed that infusions of excess insulin in dogs to cause hyperinsulinemia 
Stellenbosch University  http://scholar.sun.ac.za
18 
 
did not have any effect on BP, however did cause some sodium retention (Hall, 
Coleman, & Mizelle, 1989). These obese individuals often reach a point where their 
bodies become resistant to the actions of insulin on peripheral tissues, termed insulin 
resistance. 
1.8 Cardiac adaptations due to Hypertension 
Left ventricular hypertrophy is one of the cardiac adaptations that occur from having 
chronic HTN, and increases the risk for systolic or diastolic heart failure and sudden 
death (Panidis et al., 1984). It is an important maladaptive response to chronic 
pressure or volume overload of the left ventricle in the heart. Hypertrophy of the 
cardiac muscle is defined as an increase in size of the existing myocardial fibres in the 
heart (Ganau et al., 1992) while hyperplasia is different in the sense that the number 
of myocardial fibres increase through mitotic division (Anversa et al., 1990). LVH is the 
approximate equal thickening of all or one of the left ventricular walls, when compared 
to the other walls of the heart. 
Two types of LVH are distinguished:  
i) Global LVH is the more common type of LVH. It is categorized into two 
subtypes: concentric and eccentric. Concentric Global LVH is usually caused 
by chronic pressure overload of the left ventricle (Verdecchia et al., 1995). 
Eccentric Global LVH is mostly associated with volume overload of the left 
ventricle (Ganau et al., 1992). 
ii) Regional LVH is less common than global LVH. This type of LVH predominantly 
involves the interventricular septum. Disproportional thickening of the septum 
is usually found in embryonic and fetal hearts and is also relatively common in 
neonates. In adults, disproportional septal thickening is mostly due to systemic 
HTN, however this association is rather uncommon (Maron, Edwards, & 
Epsein, 1978). 
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1.9 Other factors in the body that might affect BP 
BP is also affected by the vascular bed via vasodilation and vasoconstriction induced 
by several substances mostly secreted by the endothelium. Nitric oxide (NO) is an 
important messenger produced by the endothelial NO synthase (eNOS) enzyme. The 
formation of NO from L-arginine by eNOS in the vascular endothelium plays a role in 
the regulation of blood pressure and in the hypotensive actions of acetylcholine (Rees, 
Palmer, & Moncada, 1989). 
 
1.10 Vascular endothelium (vascular bed adaptations) 
Vascular endothelium is the first line of defence against various harmful molecules in 
the circulation. It is therefore constantly at war with the surroundings and will 
constantly get bombarded with harmful substances. The vascular endothelium is an 
active organ in the body and plays a vital role in the basal and dynamic regulation of 
the circulation. The integrity of vascular endothelium supports the beneficial effect of 
antioxidants, anti-inflammatory, anti-coagulant and pro-fibrinolytic actions (Pierce et 
al., 1997; Weber et al., 1994). 
Endothelium releases NO under normal physiological circumstances, which is 
essential for maintaining vascular tone. Reduced NO bioavailability leads to 
endothelial dysfunction. This could be due to reduction in the expression of eNOS 
(Wilcox et al., 1997), insufficient availability of substrate and co-factors (Pou, Pou, 
Bredt, Snyder, & Rosen, 1992), even alterations in the signalling cascade that leads 
to the activation of eNOS producing NO (Shimokawa, Flavahan, & Vanhoutte, 1991) 
and last but not least the interference caused by reactive oxygen species (ROS) 
degrading the available NO (D. G. Harrison, 1997). This event preceded 
atherosclerosis and CVD complications such as HTN, T2D, strokes and heart failure 
(Al Suwaidi et al., 1998; Meigs et al., 2004; Suwaidi et al., 2000). Functional eNOS is 
found in the endothelium and is responsible for the production of NO. Nitric oxide is 
found to be protective against these pathological changes that can lead to 
atherosclerosis and CVD complications (Albrecht et al., 2003; Harrison et al., 2003). 
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The synthesis of NO is a dynamic process and by influencing proteins that partake in 
these pathways, one can restore the function of the endothelium (van Goor et al., 
2001).  
The production of NO by eNOS is a fundamental determinant in cardiovascular 
homeostasis; it regulates BP, vascular remodelling and angiogenesis (Al Suwaidi et 
al., 2001; Rees et al., 1989; Ridnour et al., 2005). Functional eNOS is indirectly 
activated by physiological and metabolic stimuli, laminar shear stress, and receptor 
dependent agonists (Balligand, Feron, & Dessy, 2009; Chen et al., 1999; Montagnani, 
Chen, Barr, & Quon, 2001). Once activated eNOS oxidises L-arginine to L-citrulline 
and NO (Palmer, Rees, Ashton, & Moncada, 1988). 
Uncoupling of eNOS results, in the formation of superoxide (O2-) instead of NO which 
causes endothelial dysfunction (Mata-Greenwood et al., 2006). The mechanism that 
leads to endothelium dysfunction starts with a reduced bioavailability of NO and the 
increased production of O2- and ROS in the wall of the arteries. This enhances the 
production of NADPH-oxidases (Knuckles, Lund, Lucas, & Campen, 2008). NADPH-
oxidases readily react with NO to form peroxynitrite (ONOO-). An essential eNOS 
cofactor (6R-) 5, 6, 7, 8-tetrahydrobiopterin (BH4) is highly sensitive to oxidation by 
ONOO- (Thum et al., 2007). With BH4 deficiency, reduction of O2 becomes uncoupled 
from NO synthesis, thereby converting eNOS to a superoxide-producing enzyme 
(Mata-Greenwood et al., 2006). 
Hypertension appears to have a complex association with endothelial dysfunction. 
Since it was first demonstrated by Altan (1989) that the vasodilator action of 
acetylcholine (ACh) was mediated directly by releasing a substance from the 
endothelium in rat aorta, there has been a considerable interest in the function of 
vascular endothelium in HTN (Altan, Karasu, & Ozuari, 1989; Van de Voorde & 
Leusen, 1984; Van de Voorde & Leusen, 1986). 
Endothelial cells synthesise and release many potent vasoactive substances including 
prostacyclin; endothelium derived relaxing factor (or NO), endothelium-derived 
hyperpolarising factor, thromboxane A2, and endothelin (Rees et al., 1989; Ridnour et 
al., 2005; Yoshizumi et al., 1990). It has been suggested that these vasoactive 
substances play a crucial role in regulating BP, regardless of obesity. 




1.10.1 Nitric Oxide 
As described above, nitric oxide is a gas, capable of moving across cell membranes, 
a characteristic that enhances its biological activity. It is produced by eNOS in vascular 
endothelial cells and has proven to be a potent vasodilator. Vasoactive substances 
such as acetylcholine (ACh), adenosine diphosphate (ADP), histamine and 
phenylephrine (PE) trigger the release of NO by the endothelial cells. Blocking the 
release of NO from endothelial cells in rats by administrating an NOS inhibitor, induced 
HTN (Arnal et al,. 1993). Interestingly, the chronic blockade of NO synthase by NG-
nitro-L-arginine-methyl ester (L-NAME) also induces HTN; however it can be 
prevented by antagonists such as ACE 1, Angiotensin II receptor antagonists (ARBs) 
and calcium channel blockers (Arnal et al., 1993). 
Hypertension was also induced in mice lacking the gene for NOS (Huang et al., 1995). 
This suggest that the continued release of NO by the endothelium plays an important 
role in the contraction and relaxation of vascular smooth muscle and that disrupting 
this role of NO in the endothelium, can lead to endothelial dysfunction and in turn to 
HTN. 
 
1.10.2 Reactive oxygen species 
Reactive oxygen species (ROS) are produced from different metabolic processes and 
play an important role in the human body. Reactive oxygen species can damage or 
protect different tissues, including those of the cardiovascular system. Research has 
also demonstrated an association between ROS and the development of HTN, 
through experiments which included the manipulation of the redox state (Laursen et 
al., 1997). Reactive oxygen species can affect multiple tissues, directly or indirectly. 
In the vasculature, they induce contraction which eventually leads to endothelial 
dysfunction (Auch-Schwelk et al., 1989; Torrecillas et al., 2001). Evidence also 
suggests that ROS can increase BP by the stimulation of the heart rate and force of 
contraction (Vaziri, Wang, Oveisi, & Rad, 2000). This suggests that ROS may 
contribute to chronic HTN and thereby induction of myocardial hypertrophy. 
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Furthermore, ROS do not only act through the vasculature, but also through the 
kidneys and the CNS (Ando & Fujita, 2012; Baud & Ardaillou, 1993; Fujita et al., 2012; 
Jin et al., 2006). The kidneys play an important role in the regulation of BP and are 
therefore also likely to be targeted by ROS. Therefore all the influence that ROS exerts 
on the different targeted tissues contributes to inducing HTN in the end. 
 
1.11 Connection between Obesity and Hypertension 
As discussed above, obesity has often been seen to co-exist with other risk factors for 
chronic diseases of lifestyle, such as HTN and diabetes. Obesity and HTN have both 
been identified as independent risk factors involved in the development of vascular 
dysfunction, renal disease and diabetes. 
The direct, positive relationship between BP and cardiovascular risk has been 
established and is well known (He & Whelton, 1999; Kannel, 1996; Kannel, Schwartz, 
& McNamara, 2009; Stamler et al., 1993; Wilson et al., 1998). This has been identified 
in men and women, young and old individuals, people from different racial groups, 
people from different countries and those with normotensive or hypertensive BP 
(Fiebach et al., 1989; Steyn et al., 2001; Tibazarwa et al., 2009). 
Obesity has also been associated with an increase in BP, however it remains unclear 
how excess adipose deposits can raise BP. Some of the factors thought to be 
responsible for this link are hyperinsulinemia and dyslipidaemia. 
 
1.12 Blood pressure classifications 
With all the new data available concerning the risk of HTN and the impressive increase 
in the risk of CVD associated with levels of BP previously described as normal, the 
Joined National Committee (JNC 7) on Prevention, Detection, Evaluation and 
Treatment of High Blood Pressure report has introduced a new classification of BP in 
their 7th report (Chobanian et al., 2003; Cornelissen & Fagard, 2005). 
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Table 1-2 provides a classification of BP for adults age 18 and older. On average, two 
or more properly measured seated BP readings were taken during each visit to help 
base this classification system. Classification of BP changed between the JNC 6 report 
which was published in 1997, and the new JNC 7 report from 2003 (Chobanian et al., 
2003). In the JNC 7 a new category has been added called ‘prehypertension’. In 
addition, they combined stage 2 and 3 HTN. The reason for creating this new group is 
that patients with prehypertension are at risk of progressing to HTN. Similarly, those 
in the 130-139/80-89 mmHg BP range area have an even greater risk of developing 
HTN. 
Table 1-2: Classification of Blood Pressure for Adults Age > 18 Years in JNC 6 categories to JNC 7 
categories adapted from (Chobanian et al., 2003). 
 
From Table 1-2 HTN cut-off point is classified as; systolic pressure greater than 140 
mmHg or a diastolic pressure greater than 90 mmHg or both. 
Despite the progression in prevention, detection, treatment and control of HTN it still 
remains an important public health problem. 
Therefore it is referred to as the ‘silent epidemic’ of our time! 
 
1.13 Benefits of reducing BP 
BP alone has been used to determine whether a patient should adjust his lifestyle or 
if a patient should make use of antihypertensive medication as a treatment option. A 
number of studies found that a high BP level, both SBP and DBP leads to an increased 
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risk of CVD, stroke and renal failure (He & Whelton, 1999; Kannel, Wolf, Verter, & 
McNamara, 1996; Kannel et al., 2009; MacMahon et al., 1990). Even the smallest 
reduction in high BP has been shown to be protective in the long run. HTN has 
therefore been identified as the most important modifiable risk factor to treat and 
reduce the chance of developing CHD, congestive heart failure, ischaemic disease, 
stroke, myocardial infarction, end stage-renal disease (ESRD), LVH, blindness and 
peripheral vascular disease (He & Whelton, 1999; Ogden, He, Lydick, & Whelton, 
2000; Whelton et al., 1992; Whelton et al., 2002). Although most studies suggest that 
the association of SBP and CVD is stronger than that of DBP, a Nigerian study 
delivered contradictory results. According to this study, an increase in DBP of 20 
mmHg resulted in a significant mortality rate among affected individuals (Kaufman et 
al., 1996). An elevated DBP may therefore be just as detrimental as elevated SBP, 
regarding the risk for CVD.  
The main objective of treating HTN is to lower a patient’s BP as this reduces the 
absolute risk of premature death and disease, primarily by reducing their risk of CVD 
(Ogden et al., 2000). Different studies have indicated different values of reduction in 
BP that can be seen as beneficial. There is no exact value stipulated by what you have 
to reduce BP in order to see the associated benefits. Even a reduction of 3-12 mmHg, 
would be beneficial and the larger the reduction (e.g. 20 mmHg) achieved, the greater 
the benefits. 
A study done by Ogden et al. (2000) calculated a reduction value of 12 mmHg to be 
of some benefit. This represented the average BP reduction that was observed from 
randomized controlled trials which were conducted to test the efficacy of 
antihypertensive agents (Ogden et al., 2000). Once again, if a larger reduction in SBP 
is observed, even greater benefit is expected (He & Whelton, 1999). 
In another clinical trial, where antihypertensive therapy was used over a 4 year period, 
a reduction of 12 to 13 mmHg in the systolic BP was associated with reductions in 
stroke incidence averaging 35-40%; myocardial infarction 20-25%; and heart failure 
more than 50% (Neal, MacMahon, Chapman, & Blood Pressure Lowering Treatment 
Trialists' Collaboration, 2000).  




Figure 1-1: Benefits of reducing high blood pressure. Shown in the figure, a small decrement in the systolic 
BP is likely to result in substantial reduction in the risk associated with HTN and cardiovascular disease 
adapted from (J. Stamler et al., 1993). 
 
1.14 Lifestyle Modifications for the prevention of hypertension 
The adoption of a healthy lifestyle is critical for the management and prevention of 
high BP. Major life style modifications or changes which have been shown to lower BP 
include physical exercise (Cornelissen & Fagard, 2005; S. P. Whelton, Chin, Xin, & 
He, 2002), weight loss in overweight and obese individuals (He et al., 2000), and the 
adoption of a healthy diet. An example of a healthy diet would be the Dietary 
Approaches to Stop HTN (DASH) (Sacks et al., 2001; Appel et al., 1997) discussed in 
1.16. Some studies have shown that even alcohol consumption, when done in 
moderation, can be beneficial to one’s health. Alcohol reportedly reduces the risk of 
developing CVD (Xin et al., 2001). Despite the abundance of pharmaceutical options 
available for the treatment of HTN, lifestyle modification remains an important 
approach in the management of BP. 
 
1.15 Physical exercise 
Physical activity is essential for long term weight control (Fagard & Cornelissen, 2007). 
This is also the most poorly complied with strategy to help with weight reduction. The 
reason for this is that it requires a considerable amount of time, effort and thought from 
the patient’s side. Furthermore, even in the absence of weight loss, increased physical 
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activity is associated with other desirable outcomes namely reduction in BP, body fat, 
waist circumference, lower blood lipids, improved glucose homeostasis, improved 
insulin sensitivity and endothelial function, amongst others (Kelley & Kelley, 2008). 
Physical activity is therefore not only important for the management of HTN but also 
for the prevention of CVD (Cornelissen & Fagard, 2005). 
When considering the type of physical exercise, endurance or resistance training is 
recommended for effective outcomes. Studies indicate that both of these types of 
exercise may result in a reduction in BP (Cornelissen & Fagard, 2005; Croymans et 
al., 2013). Physical inactivity is defined as ≤150 mins of moderate to vigorous activity 
per week. Hypertensive individuals are encouraged to start with low-impact, moderate 
intensity physical activity (e.g. walking) of short duration (for example 30 mins) on most 
days of the week (Whelton et al., 2002).  It is also recommended that healthy 
individuals partake in similar physical activity for short periods (30min) in order to help 
prevent HTN (Obesity: Preventing and Managing the Global Epidemic. Report of a 
WHO Consultation,. 2000). 
The effect of physical activity on BP is shown to be more pronounced in hypertensive 
patients than normotensive individuals. Therefore, exercise contributes to the control 
of BP in hypertensive patients and is likely to contribute to the prevention of HTN in 
normotensive individuals. 
 
1.16 Weight reduction/ Loss 
One of the most compelling reasons for recommending weight reduction is that weight 
loss in both obese and lean people have been demonstrated to reduce arterial 
pressure in both normotensive and hypertensive individuals, but little is known about 
the mechanism by which this occurs. Not only does it reduce the BP but also improves 
the carbohydrate tolerance and decreases serum lipids, thereby diminishing these two 
factors. All of these factors will reduce the chance of CHD (Wilson et al., 1998). 
Weight reduction is the only antihypertensive regimen that decreases BP in both 
normotensive as well as hypertensive patients (Su et al., 1995). This was one of the 
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few therapeutic strategies for HTN in use before the advent of adequate 
pharmacologic therapy. This association between weight and HTN has been 
demonstrated in most populations, in both industrialized and non-industrialized 
societies (rural and urban societies in RSA) (Berchtold et al., 1981; Berchtold et al., 
1982). 
Weight reduction can be increased by combining it with physical activity (as mentioned 
earlier, this is one of the fastest and best ways to treat HTN) and a diet specifically 
designed to keep a healthy balanced lifestyle. In recent years specialized diets have 
been modified in trials to incorporate several nutritional recommendations for lowering 
BP (Appel et al., 2006). 
One example is the DASH diet. This diet focuses on fruits and vegetables and is high 
in fibre and low in fats (Appel et al., 1997).  It also encourages increased intake of 
potassium and calcium while reducing sodium intake. The DASH diet was found to 
lower BP substantially in all patients and even more so in hypertensive patients. By 
reducing the salt intake in combination with the DASH diet, BP may be lowered even 
further (Sacks et al., 2001). Therapeutic weight reduction in obese, hypertensive 
individuals has been able to substantially lower their BP. This effect can also occur 
without a reduction in salt intake and it is thought to be a cause and effect relation 
rather than a more complicated association with a third factor. 
As this relationship between diet and HTN has been known for some years, it is 
advisable to consume a diet that is rich in fruits and vegetables and low in saturated 
fat content. Weight reduction should be the first line of treatment in every hypertensive 
patient, obese or non-obese. 
Weight loss does not only reduce BP, but can also improve the efficacy of 
antihypertensive agents, thereby allowing administration of lower doses (Modan et al., 
1991). It has also been demonstrated in less severe cases that hypertensive patients 
could discontinue antihypertensive drug therapy and use nutritional means to manage 
and control their BP (Stamler et al., 1987). Patients on multiple antihypertensive 
medication can also benefit from weight loss as it will result in decreasing the number 
and dosage of drugs they need to control their BP, thereby decreasing the side effects 
of medication as well as the cost involved. 
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Although regular controlled alcohol intake is shown to be beneficial to your health and 
can be cardio protective, alcohol consumption should still be limited to no more than 
30 ml of ethanol per day in most men and no more than 15 ml of ethanol per day in 
women and lower weight persons (720 ml of beer, 300 ml of wine or 60 ml of whisky) 
(Chobanian et al., 2003). Alcohol drinking has been associated with a reduction in BP 
through epidemiological studies (Xin et al., 2001). Xue Xin et al. (2001) showed that 
alcohol consumption in moderation as a means to prevent and treat HTN can strongly 
be supported. The positive association between alcohol intake and BP can be 
important modifiable risk factors for HTN among populations. 
 
1.17 Pharmacotherapy 
Because weight reduction alone may not be sufficient and effective to treat BP in the 
long-term, pharmacological treatment may be necessary in most cases. In the majority 
of patients, controlling systolic HTN, which is a more important CVD risk factor than 
DBP, can be achieved by pharmacological input.  
Currently, the control rates for initiating antihypertensive drugs are SBP ≥ 140 and 
DBP ≥ 90 (or stage 2). There are excellent clinical outcome trials showing data that 
lowering BP will reduce the complications of HTN. Several classes of antihypertensive 
drugs are available on the market to target different mechanisms in your body, which, 
in turn, leads to a reduction in BP. They include angiotensin-converting enzyme (ACE) 
inhibitors (ACEIs), angiotensin receptor blockers (ARBs), beta-blockers (BBs), 
calcium channel blockers (CCBs) and the thiazide-type diuretics. Only when clinicians 
fail to prescribe lifestyle modifications, adequate antihypertensive drugs or appropriate 
drug combinations, inadequate BP control may result.  
Thiazide-type diuretics have been the basis of antihypertensive therapy in most 
outcome trials (Psaty et al., 2002). These drugs are among the most important and 
most widely used. The BP lowering effect of these drugs is attributed initially to a 
reduction of intravascular volume and cardiac output, both of which may benefit obese 
individuals. However, the drawback is that both short- and long-term administration of 
diuretics may result in enhancement of the SNS activity and activation of the renin-
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angiotensinogen system. Diuretics do not seem to affect weight.  In the 
Antihypertensive and Lipid Lowering treatment to prevent Heart Attack Trial (ALLHAT), 
diuretics were shown as the best first-line treatment for cardiovascular complications 
of HTN (Flack, Nasser, & Antihypertensive and Lipid-Lowering Treatment to Prevent 
Heart Attack Trial (ALLHAT, 2003; Hollenberg, 2003). Diuretics enhance the 
antihypertensive efficacy when used in combination with other antihypertensive 
medication (multidrug regimens) and can be useful in achieving BP control in 
hypertensive individuals. Diuretics are also more affordable than other 
antihypertensive agents. Despite these findings, diuretics still remain underutilized 
(Psaty et al., 2002). 
It is advised that thiazide-type diuretics should be used as initial therapy for most 
patients with HTN, either alone or in combination with one of the other classes of drugs 
(ACEIs, ARBs, BBs, and CCBs) (Chobanian et al., 2003). 
As discussed previously, the Angiotensin-converting enzyme (ACE) inhibitors 
(ACEIs), block the action of ACE and thus stops the conversion of Ang I to Ang II. 
Angiotensin-converting enzyme inhibitors have also been recorded to decrease the 
secretion of ALD and vasopressin and sympathetic nerve activity. Angiotensin-
converting enzyme inhibitors as monotherapy greatly reduces BP through the 
mechanisms mentioned. 
ARBs (angiotensin receptor blockers):  It was mentioned earlier that Ang II is the key 
component in the RAAS. It binds to AT1 receptors leading to development of HTN, 
secretion of ALD, reabsorption of sodium and inflammation in some instances. Soon 
after the different receptor types were discovered, they became a logical therapeutic 
target, since these ARBs block the action of Ang II at the receptor level rather than the 
synthesis thereof. In addition to being an effective antihypertensive agent, it also 
improves insulin sensitivity and decreases SNS activity, which could be beneficial in 
obese HTN. 
The Renin Inhibitors, with renin as the initial and rate limiting step of the RAAS, was a 
logical therapeutic target to consider for antihypertensive medication. The inhibition of 
renin is focused towards decreasing the plasma renin activity (PRA). By doing so, it 
also decreases the downstream effects such as a reduction in Ang I and II, ALD and 
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consequently also a reduction in BP. Although it was initially thought to be an effective 
therapeutic option, the pharmacological activity of these early renin inhibitors could 
only be achieved through intravenous injections. Creating an oral renin inhibitor was 
rather difficult due to potency, duration of action and low bioavailability of the oral 
drugs. Research was halted in the 1990 to explore other therapeutic agents affecting 
the RAAS. 
There are also the CCBs available on the market. This class of antihypertensive 
agents exert potent peripheral vasodilator and a mild natriuretic action. 
Β-adrenergic blocking agents (or BBs) are potentially useful in the treatment of obesity 
derived HTN (Williams et al., 2004). Administration of BBs to treat HTN has been 
shown to reduce plasma renin levels by blocking the sympathetic mediated release of 
renin by the kidneys. This reduction in PRA was closely correlated to a reduction in 
BP. Beta-blockers have also been demonstrated to decrease the secretion of ALD 
from the adrenal glands, thereby  helping to decrease BP in both a renin dependent 
and independent manner (Pettinger et al., 1976; Vandongen, Peart, & Boyd, 1973). 
Beta-blockers have also been shown to decrease cardiac output which will decrease 
BP (Frohlich, Tarazi, Dustan, & Page, 1968). 
Some individuals do not respond to monotherapy and may need to take a combination 
of drugs to lower their BP (Chobanian et al., 2003; European Society of Hypertension-
European Society of Cardiology Guidelines Committee, 2003). This will increase the 
effect of the drugs thereby leading to a greater reduction in BP. Unfortunately, this may 
result in more side effects and possible drug-drug interactions. It will also increase the 
cost of the antihypertensive therapy thus making it more expensive and less 
accessible to a large part of the public. Because it is a chronic disease, HTN is a 
burden not only for the patient but also for the health care system of a country.  
Despite the high prevalence of obesity and HTN, the efficacy and safety of 
antihypertensive agents currently available for the treatment of high BP, still leaves 
room for improvement and should be studied adequately to prevent morbidity and 
decrease mortality (L. Hansson et al., 1999b). There is therefore a need for constant 
research into alternative pharmacotherapies that may be more effective, reliable and 
readily available. 




Figure 1-2: Summary of available Hypertension treatment. 
 
1.18 Herbal and supplemental treatment options 
For thousands of years indigenous cultures have been using native herbal 
supplements in the US, the Far East and in Africa for the treatment of various ailments. 
This resulted in recent resurgence in its popularity among consumers in the West 
(Tindle, Davis, Phillips, & Eisenberg, 2005). In the US it is estimated that more than 
15 million people consume herbal remedies or high dose vitamins. People’s growing 
preference for herbal treatments may be attributed to a number of influencing factors 
including pain syndromes, depression, anxiety disorders, general wellbeing and health 
awareness, as well as the increase in cost of conventional medicines  and the belief 
that a more natural  drug will be a safer or healthier option (Eisenberg et al., 1998). 
1.19 Indigenous Herbs 
In recent years, South Africa has developed a keen interest in the field of ethno-
pharmacology. Specifically, the effects of indigenous plants and indigenous medicine 
are being researched for possible development of useful medication to treat various 
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medical conditions. This is simply because in South Africa we are blessed with a great 
and vast diversity of Fauna and Flora. Examples of traditional herbal remedies found 
in South Africa include Aloe Vera (Vogler & Ernst, 1999), Prosopis Glandulosa 
commonly known as “honey mesquite” (George, Lochner, & Huisamen, 2011), Wilde 
dagga (Leonotis leonurus) (Ojewole, 2005), the African wild potato, a reputed immune-
booster and known as Inkomfe, Cancer bush (Sutherlandia Frutescens) and Olea 
europaea sub Africana (African wild olive) (Van Wyk, 2011). If the efficacy of these 
herbs/products can be confirmed by scientific research it can potentially provide an 
effective, accessible alternative and affordable way of treatment for various illnesses 
plaguing the African population. They are widely available and could well be one of 
our greatest and most valuable natural resources. 
 
1.20 Why Buchu? 
We were approached by Cape Kingdom Nutraceuticals (Pty) Ltd who requested that 
we investigate the effects of Buchu on HTN and the associated effects thereof. 
Buchu is the common name for Agathosma Crenulata and A. Betulina, which are two 
indigenous aromatic plants found exclusively in the Cape region of South Africa. They 
are part of the Cape Floral Kingdom (FYNBOS) and are particularly abundant in the 
mountainous areas of the Cape. These shrubs from the Rutaceous family are 
harvested and used for the production of commercially important products such as 
Buchu oil (Moolla & Viljoen, 2008). They are probably the best known herb for their 
medicinal properties, both locally and internationally. 
Buchu was discovered more than 300 years ago in South Africa. Here, the Khoisan 
used it in their everyday life as a traditional remedy for various ailments and as an aid 
to longevity. When the European settlers arrived in the late 1800 and 1900’s this 
became a highly prized and a scarce commodity. Since then, the Buchu industry has 
grown exponentially. In the modern day it is still used by the Khoisan, as well as in the 
cosmetics, food, fragrance and flavour industry. 
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Over the years many claims have been made regarding the medicinal properties of 
Buchu, including the belief that it is a natural diuretic.  Buchu oil has also been used 
in the investigation of antimicrobial -, antioxidant - and anti-inflammatory activity in 
recent years. Since then there has been a growing interest in the medicinal properties 
of indigenous herbal plants, worldwide (Moolla & Viljoen, 2008).  
 
1.20.1 Antimicrobial activity  
A number of studies evaluated antimicrobial activity of Buchu by using the extracted 
hydrodistilled essential oil from both Agathosma species to perform minimum inhibitory 
concentration assays. Both Moolla et al. (2008) and Viljoen et al. (2006) showed that 
the oil was active against pathogens. The pathogens tested were Bacillus cereus, 
Staphylococcus aureus, Klebsiella pneumonia and Candida albicans. These results 
indicated that both extracts possess moderate antimicrobial activity (Viljoen et al., 
2006). 
 
1.20.2 Antioxidant Activity 
A study by Moolla et al. (2008) showed that the Agathosma species are rich in 
flavonoids, a group of phytoconstituents known for their antioxidant activity (Moolla & 
Viljoen, 2008). Although they contain flavonoids, studies have shown that the 
extracted oil exhibit little free radical scavenging activity compared to the standard of 
ascorbic acid (Moolla, Van Vuuren, Van Zyl, & Viljoen, 2007). 
 
1.20.3 Anti-inflammatory activity 
Inflammation is part of our innate immune response which is intended to protect and 
eliminate the cause of cell injuries. During inflammation there is an increase in the 
production and release of pro-inflammatory cytokines (such as IL-6 and TNF-alpha), 
which are responsible for initiating inflammation that cause the diluting, neutralizing 
and removing of insulting agents in order to allow the healing process to start. 
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Reducing the amount of pro-inflammatory cytokines by blocking some of the pathways 
associated with them, one can brunt the inflammation response by pro-inflammatory 
cytokines and decrease the amount of inflammation caused by them. Buchu oil is said 
to block the synthesis of 5-lipoxygenase (LOX) products in vitro (Viljoen, Moolla, Van 
Vuuren, Van Zyl et al., 2006; Moolla & Viljoen, 2008). 5-LOX is the key enzyme which 
produces leukotrienes and is involved in a variety of inflammatory diseases. 
 
1.21 Motivation for the Study 
South Africa is currently experiencing a mass movement of people from rural to urban 
communities in search of work, education or both. Many of them erect shacks made 
of tin, wood and cardboard forming ‘shantytowns’. They live in unhealthy 
circumstances, with little or no sanitation, fresh running water or health care support 
from the public sector. The people in these communities undergo lifestyle 
modifications to adapt to the urban life. These urban migrants develop higher body 
weights (BMI), pulse rates and a possible increase in urinary sodium/potassium ratios 
than those who remain in the rural areas (Jennings et al., 2010; Rush et al., 2007; 
Senekal, Steyn, & Nel, 2003). This is due to a marked change in their diet which 
consists of a higher sodium and calorie intake from fast food services around every 
corner and less fresh fruit and vegetables which would be giving them the necessary 
dietary supplements to help manage or keep their BP lower. All this contributes to 
people undergoing a health transition that leads to higher levels of BP.  
Most people in these townships do not have the money to afford a healthy balanced 
meal. Moreover, they do not have time to visit a clinic or a healthcare facility especially 
since services within the public health sector are stretched so far in some places that 
it is often understaffed and underfunded. This leaves a huge gap in HTN detection and 
prevention. Even individuals who are able to see a doctor in the public or private sector 
and get diagnosed with high BP or HTN are faced with the challenge of receiving 
effective treatment. The medication available for HTN treatment is expensive and 
many South Africans cannot afford medical aid. This means that they must either pay 
for their prescriptions and medication themselves, or sacrifice many hours in a long 
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queue to collect it at a clinic. As a result many people who have been diagnosed with 
HTN are not interested in getting the necessary treatment to decrease their BP. Apart 
from regular physical exercise there are not many alternative treatments available for 
HTN.  
Not only does HTN affect the people coming from rural areas but also the urban 
population of South Africa living in cities and towns (Puoane et al., 2002). The stress 
associated with work, unemployment and the pressure of providing for your family are 
all factors to be considered as risk factors for an increase in BP. Additionally, smoking 
and the excessive use of alcohol add to the problem as both can lead to an increase 
in BP.  
Since the necessary health awareness and treatment to prevent the spread of an on-
going epidemic of HTN is not available yet, an inexpensive and widely available 
substance like Buchu may be an alternative to treat HTN. Despite being ranked 
amongst South Africa’s most important medicinal plants and commonly considered a 
panacea, the biological activity remains unknown and poorly explored. Claims 
regarding its medicinal properties and effects are mostly speculative and 
unsubstantial. The purpose of this research study was therefore to credit some of the 
claims that are given to this medicinal herb. 
Should these claims be validated by the present research, the implications will be vast. 
Specifically, it will mean that South Africans suffering from HTN will have an alternative 
treatment option which is affordable, effective and readily available.  
 
1.22 Hypothesis 
We hypothesized that the ingestion of Buchu water, as supplied by Cape Kingdom 
Nutraceuticals (Pty) Ltd, will be able to reduce the BP of hypertensive rats by at least 
10 mmHg, the minimum reduction to be considered protective. 
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1.23 Specific Aims 
The specific aims of this study were to: 
1) Test the effect of ingestion of Buchu water on the BP of diet induced hypertensive 
as well as normotensive rats when given as pre-treatment. 
2) Test whether Buchu water will have any effect on HTN in rats when used as 
treatment. 
3) Test whether Buchu water has any effect on endothelial function using aortic rings 
from control and hypertensive rats. 
4) Determine the expression and/or activation of signalling proteins involved in NO 
production in the endothelium (pPKB/ Akt, AMPK, eNOS). 
5) Determine whether Buchu water treatment has any insulin sensitizing effects in 
cardiomyocytes prepared from insulin resistant rats to determine possible 
cardiovascular effects.  
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CHAPTER 2: Materials & Methods 
2.1 Materials 
The reagents used in this study were bought from different companies such as:  Merck 
NT laboratory supplies (Pty, Ltd) (NaCl, KCl, CaCl2, KH2PO4, NaHCO3, MgSO4, 
d-glucose, Na+ pyrophosphate, Folin Ciocalteus Reagent (Folin C), 2-[H3]-D-
deoxyglucose, NaOH, sodium dodecyl sulphate (SDS), Tris (hydroxylmethyl) 
aminomethane, acrylamide, fructose). Sigma-Aldrich Life Science (ammonium 
persulfate (APS), HEPES, 2,3-butanedione monoxime (BDM), insulin, pyruvate, 
cholesterol, mecarpto-ethanol, N,N,N,N-tetramethylethylenediamine (TEMED), 
Ponceau-s red, streptozotocin, phenylephrine (PE), acetylcholine (ACh), 
phenylmethylsulphonyl fluoride (PMSF), Triton X-100). Millipore (Millipore enzyme 
linked immunosorbent assay (ELISA) kit).  Roche Diagnostics, (bovine serum 
albumin (BSA)). Amersham Biosciences, (enhanced chemiluminescence (ECL) 
Western blotting detection reagents, anti-rabbit lg, horseradish peroxidase linked 
whole secondary antibody). Cell Signaling technology, (Total and phospho-PKB/Akt 
(Ser473) antibody, total AMPK and phospho-AMPK-α (Thr172) antibodies, total 
eNOS). Bayer (SA) (Euthanaze). Collagenase Type II --the Collagenase Type II was 
purchased from Worthington Biochemical Corporation (Lakewood, NJ). Pro-10 
Laboratories Casein, Protein Labs Ltd (Birmingham, UK). Sime Darby Hudson & 
Knight (Pty) Ltd (Boksburg, South Africa), Holsum (vegetable fat). Buchu water – was 
supplied by the product manufacturer, Cape Kingdom Nutraceuticals (Pty) Ltd 
(Cape Town, South Africa). Siemens Coat-a-Count RIA: Aldosterone & Insulin. 
Abcam Ltd (Cambridge, England), ELISA – C-peptide, Aldosterone, Tumour Necrosis 




Age and weight matched male Wistar rats were used in this study. All animals were 
obtained from the University of Stellenbosch Central Research Facility. They received 
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free access to water and food under the 12 h dark/light cycle (light from 6:00 a.m. to 
6:00 p.m.) with temperature and humidity kept constant at 22ᵒC and 40%, respectively. 
This study was assessed and approved by the Committee for Ethical Animal Research 
of the Faculty of Health Sciences, University of Stellenbosch (SU-ACUM11-00003) 
and animals were treated according to the revised South African National Standard 
for the Care and Use of Animals for Scientific Purposes (South African Bureau of 
Standards, SANS 10386, 2008). 
 
2.2.2 STUDY DESIGN 
This study was divided into three major phases (see Figure 2-3). Animals were 
grouped, fed and treated during the first phase, prior to any intervention. During the 
second phase experimental procedures were performed. These were: anthropometric 
measurements, measurement of diastolic and systolic BP over 16 weeks, aorta ring 
studies, isolation of adult rat cardiomyocytes by perfusion of the hearts with 
collagenase, as well as blood and heart tissue collection. During the third phase, 
biochemical analyses of the collected samples were conducted (see Figure 2-3). 
 
2.2.2.1  Buchu administration 
Buchu water was supplied by Cape Kingdom Nutraceuticals (Western Cape, South 
Africa).This Buchu water contains a mixture of an extract of both Agathosma Crenulata 
and A. Betulina. The concentrated Buchu water was diluted and replaced the drinking 
water of the rats. It was supplied in 1.5 L containers. This was then diluted by adding 
3.7 L of fresh tap water to 1.3 L of concentrated Buchu water rendering a final 
concentration of 26% (v/v) Buchu water. Every 100 ml of diluted drinking Buchu water 
contained 26 ml of concentrated Buchu water; therefore a rat drinking 15 ml of water 
per day consumed less than 4 ml of Buchu water per day. The fluid intake of animals 
was monitored to determine whether it differed between any of the groups. Bottles 
containing Buchu solution were clearly marked throughout the 16 week period of 
Buchu administration. The diluted Buchu drinking water was stored at 4ᵒC until used. 
Drinking water with or without Buchu was measured and replaced every day. 




2.2.2.2  Grouping, feeding and treatment 
Models: 1 High-fat diet (HFD) & 2. Diet-induced obesity (DIO) 
Model 1: HFD model 
Male rats weighing 190 ± 10 g were randomly allocated to the following five groups:  
i. Group C: Control rats receiving a standard commercial rat chow and drinking 
water, without Buchu from day 1 
ii. Group C + Buchu: Control rats receiving a standard commercial rat chow and 
Buchu in drinking water from day 1 
iii. Group HFD (High Fat Diet): Rats receiving a high fat diet and drinking water 
without Buchu from day 1 
iv. Group HFD + Buchu: Rats receiving a high fat diet and drinking Buchu water 
from day 1 
v. Group HFD + Buchu week 8: Rats receiving a high fat diet and drinking Buchu 
water starting from week 8 
Animals were fed and treated for a period of 16 weeks (see Figure 2-3), with the 
exception of Group HFD + Buchu during week 8. This group was started on an HFD 
from day one but Buchu was first given to the group in week 8 by exchanging their 
drinking water with Buchu water. This was done for the remaining 8 weeks. The 
amount of food intake was measured at weekly intervals over the 16 weeks: This was 
done by measuring the amount of food supplied to the cages, amount left over and 
resulting in the amount consumed by the different groups of rats in each cage. To 
prevent the wet food from fermenting, it was stored at 4ᵒC and monitored daily. 
The HFD resulted in development of HTN in the animals (Huisamen, George, Dietrich, 
& Genade, 2013). This diet contained 40% fat, 10% casein, 10% fructose and 1% 
Cholesterol added to standard rat chow (SRC).  
Table 2-1: Diet Composition (Controls, DIO & HFD). 
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 Controls (SRC) HFD DIO 
Carbohydrates 60% 10% 65% 
Protein 30% 30% 19% 
Fat 10% 40% 16% 
Fructose -- 10% -- 
Cholesterol -- 1% -- 
kJ/100g 1272 1354 1173 
 
Control groups (C and C + Buchu) were fed a SRC consisting of 60% carbohydrate, 
30% protein and 10% fat. SRC was supplied by the animal housing division of our 
Faculty.






























Insulin, TNF-alpha, IL-6, Adiponectin, Leptin, Homocystein, C-peptide, 
and Aldosterone Assays   
Blood glucose 








Figure 2-3: HFD group: experimental protocol. 
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Model 2: DIO model 
Male rats weighing 190 ± 10 g were randomly divided into the following groups: 
i. Group C: Control rats receiving a standard commercial rat chow and drinking 
water, without Buchu from day 1 
ii. Group C + Buchu: Control rats receiving a standard commercial rat chow and 
Buchu in drinking water from day 1 
iii. Group DIO (High Fat Diet): Rats receiving a high caloric diet and drinking water 
without Buchu from day 1 
iv. Group DIO + Buchu: Rats receiving a high caloric diet and Buchu drinking water 
from day 1 
v. Group C + Metformin (positive control): Control rats receiving a standard 
commercial rat chow and Metformin in drinking water from day 1 
vi. Group DIO + Metformin: Rats receiving a high caloric diet and Metformin in 
drinking water from day 1 
The model of diet-induced-obesity (DIO) (Pickavance, Tadayyon, Widdowson, 
Buckingham, & Wilding, 1999) was used to induce insulin resistance without induction 
of HTN in the Male Wistar rats. The DIO diet was a high caloric diet consisting of 33% 
SRC supplemented with 7% sucrose and 33% sweetened condensed milk (Clover) 
with a kJ/100g content as shown in Table 2-1. 

































































































Figure 2-4: DIO groups: experimental protocol. 
 
2.2.3 Experimental Procedures 
The experimental procedures and major phases of the study are represented in Figure 
2-3 & Figure 2-4. 
2.2.3.1 Measuring blood pressure 
A non-invasive computerized tail-cuff system was used to measure the BP in the 
different groups of rats. The Kent Coda 2 Blood pressure monitor (Kent Scientific 
Corporation, Connecticut, USA) was used and allowed the measuring of two rats 
simultaneously. The warming platform had space for three housing boxes. This 
separates the rats as they undergo BP evaluation, from the vibration produced by the 
pressurized pump. 
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Prior to the actual experiment, the rats were acclimated for two weeks (14 days) with 
training/conditioning sessions (that is, sessions of unrecorded measurements). This 
was necessary for the rats to become accustomed to the tail-cuff procedure to reduce 
the variability of the real BP measurements. The BP was measured the same time on 
every day (in the morning) since BP varies according to the time of day due to its 
inherent circadian rhythm. Sessions of recorded measurements were made by a single 
investigator to prevent any stress of a different individual that may affect the outcome 
of the BP measurements.  
The warming platform had 3 levels of temperature control; we used Level 2 ≈ 35ᵒC. 
The Occlusion (O)-cuff and Volume Pressure Recording (VPR)-cuffs were tested prior 
to running an experiment. Rats were handled gently and placed in the animal holders 
(or restraining holders) with a dark nose cone to calm them. Different sized animal 
holders were used for different sized rats. Two restraining holders were used for 
obtaining each reading in a single experiment. They were placed in their designated 
positions on the warming platform maintained at 35ᵒC. Rat tails were carefully 
threaded/passed through the O-cuff first and then through the VPR-cuff (13 mm long, 
with a 9 mm diameter) and immobilized by using adhesive tape. Rats were left in 
animal holders with the tail cuffs on for at least 5 minutes. This allowed the rats to get 
acclimatized to the holders and cuffs before the actual BP reading started. Each 
session included two sets of six measurements (one acclimation cycle followed by five 
reading cycles), so that a total of 10 measurements were used to determine the BP of 
each rat on a single day. Data were collected at weekly intervals over the 16 week 
period. 
 
2.2.3.2 Aorta ring Studies 
After 16 weeks of the HFD and treatment with Buchu water regime, the rats were 
anaesthetised by intraperitoneal (IP) injection of sodium pentobarbital given at the 
dose of 160 mg/kg (Lochner, Genade, & Moolman, 2003). Deep anaesthesia was 
ascertained by foot pinch before the thoracic cavity was opened and the aorta 
removed and arrested in ice-cold (4ᵒC) normal Krebs-Henseleit (KH) solution 
containing; 118.46 mM NaCl; 24.995 mM NaHCO3-; 4.748 mM KCl; 1.185 mM 
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KH2PO4-; 1.19 mM MgSO4.7H2O; 1.25 mM CaCl2.2H2O and 10 mM glucose.  All the 
excess debris, blood and surrounding tissue were removed carefully under 
magnification without damaging the aorta. Extra care was taken to avoid contact with 
the luminal surface to preserve the endothelial cells. The aorta was cut up in strips of 
3-5 mm before it was mounted in an organ bath coupled to a PowerLab system for 
experimentation.  
 
2.2.3.2.1 Solutions used in the study 
A phenylephrine (PE) solution was prepared by adding 0.00204g PE in 10 ml 0.9% 
saline to give a 1 mM PE stock.  An acetylcholine (ACh) solution was prepared by 
adding 0.0182 g ACh to 10 ml 0.9% saline resulting in a 10 mM ACh stock. 
 
2.2.3.2.2 Aorta rings relaxing/contracting Protocol 
Three different concentrations of ACh were prepared from the stock solution before 
the start of the experiment. The PowerLab system using Lab Chart 7 (ADInstruments, 
Castle Hill, New South Wales, Australia) software and the incubation system were 
calibrated using a 2 g weight. The aorta preparation was stabilized in the organ bath 
for 30 minutes and the buffer changed every 10 minutes to ensure adequate energy 
substrate supply and removal of waste products. The buffer medium was continuously 
gassed with 95% O2 / 5% CO2. The tension was kept constant at ≈1.5 g during the 
stabilization phase. The first round of contraction/ relaxation was initiated by adding 
2.5 µl of 1 mM PE to the organ bath for final concentration of 100 nM. Once it reached 
a plateau, 25 µl of the 10 mM ACh stock was added to the organ bath rendering a final 
concentration of 10 µM ACh. This was done to ensure that the endothelium of the 
preparation was undamaged, giving a normal contraction/relaxation response. 
The organ bath was rinsed twice with fresh buffer. Then the ring was allowed to 
stabilize again for 30 minutes. The buffer was changed every 10 minutes and the 
tension kept constant at ≈ 1.5 g. 
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The second round of contraction/ relaxation was started without rinsing the buffer out 
in between the addition of PE and ACh. An amount of 25 µl of 1 mM PE was added to 
the organ bath for contraction, which changed the final concentration to 1 µM. 
Relaxation, was performed in a stepwise manner, by adding ACh in 5 aliquots and 
thereby increasing the concentration slowly. This was started by adding 7.5 µl of the 
100 µM ACh stock to the organ bath, which gave a concentration of 30 nM. Another 
17.5 µl of the 100 µM ACh stock was added to the organ bath giving a concentration 
of 100 nM then 42.5 µl of the 100 µM ACh stock giving a concentration of 300 nM.  A 
further 14.3 µl of the 1 mM ACh stock was added to the organ bath to given 1 µM and 
finally 220 µl of the 1 mM ACh stock was added to the organ bath rendering a final 
concentration of 10 µM ACh. The reading was allowed to stabilize between the 
additions of the different concentrations of ACh. The % relaxation was calculated after 
each addition of ACh, so as to determine the functionality of the aorta. 
 
2.2.3.3  Isolation of adult rat cardiomyocytes (ARCM) 
2.2.3.3.1  Preparing the stock solutions for the isolation of ARCM 
Calcium-tolerant adult ventricular myocytes in an unstimulated state were prepared, 
using isolation methods previously described by Fisher et al. (1991) subsequently 
modified in our laboratory (Huisamen, Donthi, & Lochner, 2001). Stock solutions were 
prepared of the following salts: 120 mM KCl, 20 mM Na2HPO4 , 4 mM NaH2PO4 , 28 
mM MgSO4  2.56 M NaCl and a 100 mM CaCl2 stock solution. These were made up 
in milli-Q water and autoclaved before use.  
To prepare buffer A, twenty five millilitres of each stock solution was used and HEPES 
salt (1.2465 g to give a final concentration of 10 mM) was added. The pH was adjusted 
to 7.4 and the solution made up to 500 ml in milli-Q water in a volumetric flask.  The 
following solutions were prepared: (i) A 100 ml buffer A was removed from the 
volumetric flask and kept to make up Solution E. (ii) Solution A was prepared by adding 
5.5 mM D-glucose (0.39635g) and 2 mM pyruvate (0.088g) to the remaining 400 ml. 
(iii) 0.7% bovine serum albumin (BSA) (0.525 g) was added together with Fatty-acid-
free (FAF) BSA, 18 mM 2,3-butanedione monoxime (BDM) (0.134g) and 1.1 mg/ml 
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collagenase (Worthington type II) and made up to 75 ml with Solution A = Solution B.  
(iv) For Solution C, 1% BSA (0.25 g), 1% BSA FAF (0.25 g) and 100 µl CaCl2 stock 
were used. This was made up to 25 ml with Solution A and added to 25 ml Solution B 
rendering a solution containing half the concentration collagenase and BDM. (v) 
Solution D consisted of 50 ml of Solution A, with 1.25 mM CaCl2 (625 µl from the stock) 
and 1 g BSA FAF. Solution E: 50 ml of buffer A without substrates plus 1.25 mM CaCl2 
and 1 g BSA (FAF).  
 
2.2.3.3.2 Protocol for the isolation of adult rat cardiomyocytes 
The isolation procedure is based on Langendorff perfusion with a preload of 100 cm 
water. The rats were sacrificed by injecting them with 160 mg/kg pentobarbital sodium 
intraperitoneally. After reaching deep anaesthesia, as determined by lack of response 
on a foot pinch, the beating heart was removed and immediately arrested in ice cold 
buffer A. The heart was cannulated via the aorta on a perfusion rig, tied securely and 
perfused with Solution A for 5 minutes to remove all the excess blood. Hereafter 
perfusion was switched to Solution B (digestion buffer) and the heart digested in a 
recirculating manner for 15 minutes. 50 µl CaCl2 (100uM) was added and, after 
another 5 minutes, another 50 µl giving a CaCl2 concentration of 200uM. The heart 
was digested until the perfusate flowed continuously or for a maximum time of 35-40 
minutes. After digestion, the heart was removed from the cannula and the atria and 
connective tissue removed carefully. The ventricles were gently torn apart and 
incubated in 50 ml Solution C in a shaking water bath at 37ᵒC under O2 for 15 minutes. 
The calcium concentration was stepwise taken up to 1.25 mM by adding 4 X 100 µl 
plus 125 µl CaCl2 stock with one minute intervals. The digested tissue was filtered 
through a nylon mesh (200 x 200 µm) and the cells gently spun down at 100 r.p.m. for 
3 minutes at room temperature. The supernatant containing non-viable myocytes was 
aspirated and the pellet suspended in 35 ml Solution D. Viable cells were allowed to 
sediment for 5 minutes through this solution containing 2% FAF BSA to form a loose 
pellet. Only the live, healthy cardiomyocytes will settle. The pellet was resuspended in 
15 ml Solution D and left at room temperature for at least 1.5 hour under an O2 
atmosphere to slowly rotate on a belly dancer (orbital) laboratory shaker. This provided 
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the cells with time to recover from the trauma of isolation. This procedure renders in 
excess of 80% viable cells as measured by trypan blue exclusion. Afterwards, the 
pellet was allowed to settle under gravity and the supernatant removed. The cells were 
suspended in solution E and spun down into a loose pellet (3 minutes @ 100 r.p.m.) 
and washed 3 times with solution E. Cells were finally suspended in a suitable volume 
of solution E. 
 
2.2.3.4  Determination of 2-deoxy-D-3[H] Glucose (2DG) uptake by adult rat 
cardiomyocytes 
Cardiomyocytes were assayed for their ability to accumulate 2DG in a total volume of 
750 µl of oxygenated solution E as previously described (Fischer et al., 1991; Donthi 
et al., 2000; Huisamen et al., 2001). Cell aliquots were left to equilibrate for 5 minutes 
in a shaking water bath (180 strokes/minute) at 37ᵒC. Cells were stimulated with or 
without 1, 10 or 100 nM insulin for 15 minutes where after they were incubated with 
1.5 µCi/ml 2DG giving a final concentration of 1.8 µM deoxyglucose, for 30 minutes. 
This allowed the uptake and accumulation of the deoxyglucose in the cells as 
deoxyglucose cannot be metabolized. A negative control containing 400 µM phloretin, 
an inhibitor of carrier-mediated glucose uptake (GLUT-1 and GLUT-4), was included 
in the assay and this value subtracted from all values. The incubation reaction was 
also stopped by the addition of 400 µM phloretin. Following this, the cells were 
microfuged at 1000 x g for 1 minute.  The 2DG containing supernatant was aspirated 
and the cells were washed twice with buffer A. The cell pellet was then dissolved in 1 
N NaOH in a water bath at 70ᵒC for 30-40 minutes. Afterwards dH2O was added to 
yield a concentration of 0.5 N NaOH.  
In order to determine cell-associated radioactivity, 100 µl of the cell lysate was mixed 
with 3 ml of scintillation fluid and kept overnight in the dark before counting in a beta-
scintillation counter (Beckman). The remaining cell lysate was used for determination 
of protein content by the method of Lowry (Lowry et al., 1951). 2DG concentration was 
calculated as pmol 2DG/mg protein/30 min. 
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2.2.3.5  Lowry protein determination 
For protein content determination by the method of Lowry (Lowry et al., 1951); three 
BSA protein standards of known concentration were used and 0.5 N NaOH as the 
blank. The reaction buffer contained 2% Na2CO3, 2% NaK+ tartrate and 1% 
CuSO4.5H2O and was prepared directly before the assay. 1 ml of the reaction buffer 
was added to 50 µl of sample, standard or blank, mixed well and allowed to stand for 
10 minutes at room temperature. Afterwards 0.1 ml of Folin-Ciocalteu’s phenol reagent 
(1:2 dilution with distilled H2O) was added and vortexed. Tubes were permitted to 
incubate for 30 minutes. This resulted in a deep blue colour development of which the 
absorbance was read in a spectrophotometer at 750 nm against the blank. The 
unknown protein concentrations were plotted from the standard curve to determine 
their protein concentration (Lowry et al., 1951). 
 
2.2.3.6 Intraperitoneal glucose tolerance test (IPPGT) 
An intraperitoneal glucose test was performed on the rats at the end of the 16 weeks 
diet and treatment with Buchu water. After an overnight fast, rats were injected IP with 
sucrose at 1g/kg body weight. Blood samples were taken by tail prick before glucose 
administration and 1, 3, 5, 10, 15, 20, 25, 30, 60, 90 and 120 minutes thereafter. Blood 
glucose content was measured using a commercial available glucometer 
(GlucoPlusTM, Montreal, Canada). 
 
2.2.3.7 Determination of visceral fat content 
After the rats were anaesthetised and their organs (heart, kidneys and liver for further 
studies) were removed, further incisions were made exposing the fat masses in the 
viscera. The fat was removed and weighed and expressed as a percentage of the rat’s 
body weight. 
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2.2.3.8 Urine Collection and Analysis 
Rats were placed individually in metabolic cages and the urine was collected overnight 
(24 hour period). This was done during week 8 and 16 of the experimental time frame. 
The urine was collected and the amount measured to determine possible diuretic 
effects of the administered Buchu water. The samples were stored at -20ᵒC for further 
analysis.  
 
2.3 Biochemical Analysis 
2.3.1 Western blot analysis 
2.3.1.1 Tissue collection 
Aortas, which have been dissected and snap frozen in liquid nitrogen immediately after 
removal from the individual animals, were used for Western blotting. 
2.3.1.2 Lysate preparation (protein extraction) 
Approximately 3-4 cm (or 20g) of the aorta tissue was pulverised in a liquid nitrogen 
precooled mortar and pestle. Pulverised tissue was then added to tubes each 
containing 850 µl of lysis buffer (pH 7.4) containing: 20 mM Tris-HCL (pH 7.4), 1 mM 
ethylene glycol tetraacetic acid (EGTA), 1 mM ethylenediaminetetraacetic acid 
(EDTA), 25 mM NaCl, 1 mM β-glycerophosphate, 2.5 mM natriumpyrophosphate, 
0.1% (w/v) sodium dodecyl sulphate (SDS), 1 mM Na3VO2, 50 nM NaF, 1% (v/v) Triton 
X-100, leupeptin (10 µg/ml), aprotonin (10 µg/ml), 1 mM phenylmethyl-sulphonyl 
fluoride (PMSF, added immediately before use). The same lysis buffer was used for 
all lysates and proteins. The tissue and lysis buffer were then homogenised 
mechanically at 4ᵒC with a Bullet BlenderTM homogenizer (Next Advance, Inc. USA)  
using a small scoop of 1.4 mm stainless steel beads in Eppendorf tubes. The 
homogenization cycle was repeated 3 times for 1 minute with 5 minutes intermediate 
resting periods. After homogenising the samples, they were spun down in a microfuge 
(Eppendorf Mini-spin plus, Hamburg, Germany) for 10 minutes @ 15 000 r.p.m. to 
remove excess matter. Protein content of each sample was determined using the 
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Bradford determination method. Samples were diluted with lysis buffer to similar 
protein content and then with a three times Laemmli sample buffer, boiled for five 
minutes and stored at -20ᵒC until Western blot analysis was performed. Lysates were 
not kept for longer than two weeks. 
 
2.3.1.3 Bradford protein determination 
The method of Bradford (Bradford, 1976) was used to determine the protein content 
of tissue lysates because of its sensitivity to low concentrations of protein. Bradford 
reagent composition: (0.01% (w/v) Coomassie Brilliant Blue G-250, 4.7% (v/v) ethanol, 
and 8.5% (v/v) phosphoric acid). Bradford reagent stock diluted 1:5 and filtered 
through 2x filter paper. Diluted bovine serum albumin (BSA) of known concentration 
(5 mg/ml) was used to generate a standard curve. The BSA was diluted 1:5 (100 µl + 
400 µl dH2O) pipetted into test tubes to render a protein concentration between 1 to 
20 µg protein. The volume of BSA pipetted into the test tubes was (µl): 5, 10, 20, 40, 
60, and 80, then adjusted to 0.1 ml with Millipore water. The protein lysates was diluted 
by 1 to 5 (1:5) with dH2O in order to dilute all the detergents such as Triton X present, 
which may interfere with the assay. A suitable aliquot (5 µl) of each diluted sample 
was adjusted to 0.1 ml with dH2O and 0.9 ml of Bradford reagent was added to the 
contents in the test tubes. Samples were vortexed and incubated for 15-30 minutes. 
The absorbance was measured at 595 nm using a spectrophotometer. This was done 
by using 1 ml cuvettes against a blank prepared from 0.1 ml of Millipore H20 and 0.9 
ml of Bradford reagent. The standard curve obtained in this manner was used to 
determine the protein concentration in each of the unknown samples. Samples were 
diluted to fall on the linear portion of the standard curve.  
 
2.3.1.4 Protein separation and transfer 
Equal amounts (20-100 µg as indicated) of sample protein from the various fractions 
were separated on a 12% SDS-polyacrylamide gel with a 4% stacking gel, using the 
standard Bio-rad Mini-PROTEAN 3 System (Biorad, Life Science group, US). The 
system was filled with the running buffer (composition: 50 mM Tris, 384 mM glycine, 
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1.0% (w/v) SDS) and run for 1 hour. Proteins were transferred to a polyvinylidene 
fluoride (PVDF) membrane (ImmobilonTM P, Millipore) by electro-blotting. Membranes 
were stained with Ponceau-S red (reversible staining) for visualisation and verification 
that the protein bands were transferred to the membrane. The Ponceau-S stained 
membrane was laser-scanned and a copy saved as proof of equal loading. 
Membranes were then washed with Tris-Buffered Saline (TBS) containing 0.1% 
Tween-20 (TBS-Tween). The non-specific binding sites on the membranes were 
blocked with 5% fat-free milk powder dissolved in TBS-Tween for 1-2 hours at room 
temperature. Following the blocking procedure, the membranes were washed 
thoroughly with TBS-Tween and incubated overnight at 4ᵒC with the appropriate 
primary antibody diluted according to the manufacturer’s instructions. After the 
incubation, the membranes were washed with TBS-Tween to remove the excess 
primary antibody. The immobilised primary antibody was conjugated with a diluted 
horseradish peroxidase (HRP)-labelled secondary antibody for 1 hour at room 
temperature. The membranes were again washed thoroughly with TBS-Tween. 
 
2.3.1.5 Immunoblotting 
Protein kinase B (PKB/Akt) 
Western blotting was performed as stated above with minor adjustments for specificity. 
Fractions (20 µg protein) were loaded on a 4% stacking gel and then separated on a 
12% SDS-polyacrylamide gel. Membranes were incubated with the total-Akt or the 
phospho-Akt (Serine 473) primary antibodies (Cell Signaling Technology TM) for 5 – 
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Gels were loaded with 50 µg of proteins per lane for both eNOS. 4% stacking gel and 
7.5% SDS- polyacrylamide gel were used for the separation of the proteins. 
Membranes were incubated with the primary antibody (5 µl of eNOS in 5 ml TBS-
Tween) over night (5-16 hours) at 4ᵒC.  
AMP- activated protein kinase (AMPK)  
Western blotting was performed as mentioned above with some minor adjustment for 
specificity. Protein fractions (20 µg protein) were loaded on a 4% stacking gel and 
separated on a 12% SDS-polyacrylamide gel. Total or phospho-AMPK (Thr 172) 
primary antibody (Cell Signaling Technology TM) was used to incubate the membrane 
for 5 – 16 hours at 4ᵒC.  
 































Stellenbosch University  http://scholar.sun.ac.za
54 
 
Table 2-3: SDS-polyacrylamide gel. 
Reagent Stock 12% Gel 7.5% Gel 4% Stack gel 
dH2O distilled 3.35 ml 5.5 ml 3.05 ml 
Tris-HCl 
(pH8.8) 
1.5 M 2.5 ml 2.5 ml -- 
Tris-HCl 
(pH8.8) 
0.5 M -- -- 1.25 ml 
SDS 10% 100 µl 100 µl 50 µl 
Acrylamide 40% 3.0 ml 1.875 ml 0.5 ml 
APS 10% 50 µl 50 µl 50 µl 
TEMED 99% 20 µl 20 µl 10 µl 
 
 
2.3.1.6 Immunodetection of protein by using a Secondary Antibody 
The secondary antibody was used at a 1:4000 dilution in TBS-Tween. After 1 hour 
incubation, membranes were rinsed 3-4 times for 5 minutes each with TBS-Tween. 
Proteins were detected by enhanced chemiluminescence by making use of the 
enhanced chemiluminescence (ECL) detection reagents for 1 minute. The excess ECL 
detection reagent was drained off the membrane and light emission from the 
membrane was then captured on autoradiography film (Hyperfilm ECL, RPN 2103-
Amersham Bioscience). The ECL reagents react with the horseradish peroxidase 
coupled to the secondary antibody giving a chemiluminescence emission. The protein 
band density was quantified by laser scanning densitometry and analysed by using 
suitable software (UN-SCAN-IT, Silk Scientific Inc., Orem, Utah, US). 
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2.3.2 Blood Analysis  
2.3.2.1 Blood Collection 
Blood was drawn after an overnight fast to measure serum glucose and insulin levels. 
The blood was collected by drawing 1ml of blood directly from the carotid artery. Non-
fasting blood were collected on sacrifice of the animals from the thoracic cavity and 
transferred into serum collection tubes. The blood was allowed to clot on ice and then 
centrifuged at 3000 r.p.m. at 4ᵒC for 10 minutes. The serum was transferred to 
Eppendorf tubes and stored at -80ᵒC until further analysis was performed. 
 
2.3.2.2 Enzyme linked immunosorbent assay (ELISA) 
2.3.2.2.1 Tumor Necrosis Factor (TNF) - Alpha ELISA 
We used a commercially available TNF-alpha ELISA kit (Abcam Ltd, Cambridge, UK) 
for the quantitative measurement of TNF-alpha in the serum (previously collected and 
stored) of each rat sample.100 µl of each standard (20 000 pg/ml, 6667 pg/ml, 2222 
pg/ml, 740.7 pg/ml, 246.9 pg/ml, 82.30 pg/ml, 0 pg/ml) and serum samples were 
pipetted into the wells of a 96-well plate coated with anti-rat TNF-alpha antibody. This 
was done in duplicate and followed by an incubation period of 2.5 hours at room 
temperature. TNF-alpha present in the standards and serum samples bound to the 
wells via the immobilized antibody. All fluid was decanted and the wells were washed 
thoroughly with wash buffer. 100 µl prepared biotinylated anti-Rat TNF-alpha antibody 
was added to each well and incubated for 1 hour at room temperature. After 1 hour 
the unbound biotinylated antibody was washed away with wash buffer. 100 µl prepared 
horseradish peroxidase (HRP) - streptavidin was pipetted to each well and incubated 
for 45 minutes at room temperature. After washing the wells again with wash buffer, 
100 µl tetramethylbenzidene (TMB) one-step substrate reagent was added to each 
well and incubated for 30 minutes at room temperature. The colour developed in 
proportion to the amount of TNF-alpha bound. 50 µl of the Stop solution was pipetted 
in to each well. The colour changed from blue to yellow. The intensity of the colour 
was immediately measured on the microplate reader (FLUO-Star Omega, BMG 
Labtech) at 450 nm. 




2.3.2.2.2 C-peptide ELISA 
C-peptide levels were determined in previously stored plasma using a commercially 
available ELISA kit (Abcam Ltd, Cambridge, UK). It is a quantitative assay for detecting 
C-peptide based on the principle of Competitive Enzyme Linked Immunoassay. The 
96-well microplate is pre-coated with anti-rabbit secondary antibody. The 96-wells on 
the microplate were divided into blanks (NSB) (x2), standards (x12), positive controls 
(PQ) (x4), and samples (x78). The assay was done in duplicate to ensure accurate 
measurements and all the wells were repeatedly washed three times with 300 µl 
diluted (10x) wash buffer. All reagent and standards were prepared as instructed. 100 
µl anti C-peptide anti-body was added to each well, the plate covered and incubated 
for 1.5 hours at room temperature on an orbital microtiter plate shaker (1-2 
cycles/second). The plate sealer was removed, the plate decanted on tissue paper 
and all the excess C-peptide antibody solution discarded. The wells were washed 
three times with 300 µl diluted wash buffer. Thereafter 100 µl of samples or standards 
were added to each well and incubated as instructed for 2.5 hours at room 
temperature. All solution was discarded and wells washed three times with 300 µl 
diluted wash buffer. 100 µl of prepared horseradish peroxidase (HRP) -streptavidin 
solution was added to each well and Incubated for 45 minutes at room temperature 
with gentle shaking. The horseradish peroxidase (HRP) - streptavidin solution was 
discarded and the wells washed three times with 300 µl diluted wash buffer. 2nd last 
step: a 100 µl tetramethylbenzidene (TMB) one-step substrate reagent was added to 
each well and incubated for 30 minutes at room temperature in the dark. After 30 
minutes the 50 µl Stop solution was added. Wells were shaked by hand to mix the 
solution and absorbance was immediately read at 450 nm using a plate reader (FLUO-
Star Omega, BMG Labtech). Afterwards C-peptide concentrations were calculated. 




Figure 2-5. C-peptide ELISA Summary. 
 
2.3.2.2.3 Interleukin (IL)-6 
The IL-6 ELISA kit (Abcam Ltd, Cambridge, UK) was used for the quantitative 
measurement of IL-6 in the serum sample (previously collected and stored) of each 
rat. This in vitro enzyme-linked immunosorbent assay contained an anti-rat IL-6 coated 
96-well microplate. Standards (10 000 pg/ml, 4000 pg/ml, 1600 pg/ml, 640 pg/ml, 256 
pg/ml, 102.4 pg/ml, 40.96 pg/ml, 0 pg/ml) and serum samples were prepared in 
duplicate. 100 µl of each was pipetted into the wells followed by an incubation period 
of 2.5 hours at room temperature. IL-6 present in the standards and serum samples 
bound to the wells via the immobilized antibody. All fluid was decanted and the wells 
were washed thoroughly with wash buffer. 100 µl prepared biotinylated anti-rat IL-6 
antibody was added to each well and incubated for 1 hour at room temperature. The 
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unbound biotinylated antibody was washed away with wash buffer. 100 µl prepared 
HRP- streptavidin solution was pipetted to each well and incubated for 45 minutes at 
room temperature. After washing the wells again with wash buffer, 100 µl TMB one-
step substrate reagent was added to each well and incubated for 30 minutes at room 
temperature. The colour developed in proportion to the amount of IL-6 bounded. 50 µl 
of the stop solution was pipetted in to each well. The colour changed from blue to 
yellow. The intensity of the colour was immediately measured on the microplate reader 
(FLUO-Star Omega, BMG Labtech) at 450 nm. 
 
2.3.2.2.4 Adiponectin ELISA 
Rat adiponectin levels were measured using a commercially available rat ELISA kit 
(Abcam Ltd, Cambridge, UK) which is a quantitative enzyme-linked immunoassay 
technique. A 96-well adiponectin microplate has been pre-coated with polyclonal 
antibody specific for adiponectin. Standards (100 ng/ml, 50 ng/ml, 25 ng/ml, 12.5 
ng/ml, 6.250 ng/ml, 3.125 ng/ml, 1.560 ng/ml, 0 ng/ml) and serum samples were 
prepared in duplicate. 50 µl of each was pipetted into the wells followed by an 
incubation period of 1 hour at room temperature. Adiponectin present in the standards 
and serum samples bound to the wells by the immobilized antibody. All fluid was 
decanted and the wells were washed 5 X with washing buffer. 50 µl prepared 
biotinylated anti-rat adiponectin antibody was added to each well and incubated for 1 
hour at room temperature. The unbound biotinylated antibody was washed away 5 X 
with wash buffer. 50 µl prepared horseradish peroxidase (HRP) -streptavidin solution 
was pipetted to each well and incubated for 30 minutes at room temperature. After 
washing the wells again 5 X with wash buffer, 50 µl chromogen substrate was added 
to each well and incubated for 10 minutes (blue colour develops) at room temperature. 
The colour developed in proportion to the amount of adiponectin bound. 50 µl of the 
stop solution was pipetted in to each well. The colour changed from blue to yellow. 
The intensity of the colour was immediately measured on the microplate (FLUO-Star 
Omega, BMG Labtech) reader at 450 nm.   
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2.3.2.2.5 Leptin ELISA 
The commercially available Leptin ELISA kit (Abcam Ltd, Cambridge, UK) was used 
for the quantitative measurement of leptin in the serum (collected and stored 
previously) of each rat. The 96-well microplate coated with anti-rat leptin antibody was 
divided according to the number of standards and samples (blanks (NSB) (x2), 
standards (x12), positive controls (PQ) (x4), and samples (x78)). Standards (8000 
pg/ml, 2667 pg/ml, 888.9 pg/ml, 296.3 pg/ml, 98.77 pg/ml, 32.92 pg/ml, 10.97 pg/ml, 
0 pg/ml) and serum samples were prepared in duplicate. 100 µl of each was pipetted 
into the wells followed by an incubation period of 2.5 hours at room temperature. Leptin 
present in the standards and serum samples bound to the wells by the immobilized 
antibody. All fluid was decanted and the wells were washed thoroughly with wash 
buffer. 100 µl prepared biotinylated anti-rat leptin antibody was added to each well and 
incubated for 1 hour at room temperature. The unbound biotinylated antibody was 
washed away with wash buffer. 100 µl prepared HRP- streptavidin was pipetted to 
each well and incubated for 45 minutes at room temperature. After washing the wells 
again with wash buffer, 100 µl TMB one-step substrate reagent was added to each 
well and incubated for 30 minutes at room temperature. The colour developed in 
proportion to the amount of leptin bound. 50 µl of the stop solution was pipetted in to 
each well. The colour changed from blue to yellow. The intensity of the colour was 
immediately measured on the microplate reader (FLUO-Star Omega, BMG Labtech) 
at 450 nm. 




Figure 2-6: Leptin ELISA Summary. 
 
2.3.3 Radioimmunoassay Assays 
Plasma insulin and ALD levels were determined in the fasting state. Blood was 
collected from the animals while they were sedated. Plasma was stored at -80ᵒC in a 
Snijders Scientific Ultracool (Tilburg, the Netherlands). Insulin and ALD was 
determined by radioimmunoassay (RIA).  
Radioimmunoassay principle: 
The RIA technique is one of the more superior analytic procedures with regards to 
sensitivity, precision, specificity and experimental simplicity. It greatly helped in 
diagnosing and advancing our understanding of endocrine physiology (Eckert & 
Strecker, 1978). Radioimmunoassay is a very sensitive technique used to measure 
the concentrations of antigens (hormone levels in the blood) by the use of antibodies. 
A fixed concentration of labelled tracer antigen is incubated with a constant dilution of 
the antiserum so that the concentration of the antigen binding to the sites of the 
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antibodies is limited. If unlabelled antigen is added to the system, there is competition 
between the labelled tracer and the unlabelled antigen for the limited and constant 
number of binding sites on the antibody. Thus the large amount of tracer antibody will 
decrease as the concentration of unlabelled antigen increases.  After the separation 
of the free and bound antibodies this can be measured. In the case of a hormone, that 
specific hormone would compete with the labelled hormone in the assay for that 
specific antibody’s binding sites. The radioactivity is measured at the end using a 
gamma scintillation counter (Perkin Elmer 1470 Auto-gamma counter). 
 
2.3.3.1 Radioimmunoassay procedure for Insulin 
All the components were brought to room temperature before the assay was 
performed (15 - 28ᵒC), as instructed by the manufacturers.  Fasting serum was 
collected as described above. Insulin levels were determined using a competitive RIA 
(Count-A-Count® Insulin Diagnostics Corporation; LA, USA). All the samples were 
analysed in duplicate during the assay. Uncoated polypropylene tubes were labelled 
for total counts (T) and non-specific binding (NSB). Insulin antibody coated tubes were 
labelled for the 7 standards (A to G), controls and samples. 200 µl of the remaining 
zero calibrator, control and samples were pipetted in their respective tubes directly to 
the bottom. 1.0 ml of 125I insulin was added to each tube and subsequently vortexed 
and incubated for 22- 24 hours at room temperature. The tubes were then decanted, 
except for the total counts and allowed to drain for 3-5 minutes. Each tube was struck 
on absorbent paper to remove moisture inside the tube. Excess liquid was blotted from 
the tubes. Removal of the excess moisture ensures a more precise assay. The 
radioactivity of each individual tube was measured in a gamma scintillation counter 
(Perkin Elmer 1470 Auto-gamma counter) for 1 minute. The standard curve was 
included to determine the concentration of the unknown samples in the tubes. 
 
2.3.3.2 Radioimmunoassay procedure for Aldosterone 
All the components were brought to room temperature before the assay was 
performed (15 - 28ᵒC), as by instruction by the manufactures. All the samples were 
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analysed in duplicate during the assay. Aldosterone levels were determined using a 
competitive RIA (Count-A-Count® Aldosterone Diagnostics Corporation; LA, USA). 
Uncoated polypropylene tubes were labelled for total counts (T) and non-specific 
binding (NSB). Aldosterone antibody coated tubes were labelled for the 7 standards 
(A to G), controls and samples. 200 µl of the remaining zero calibrator, control and 
samples were pipetted in their respective tubes directly to the bottom. 1.0 ml of 125I 
ALD was added to each tube and subsequently vortexed and incubated for 18 hours 
at room temperature. The tubes were then decanted, except for the total counts and 
allowed to drain for 3-5 minutes. Excess liquid was blotted from the tubes and the radio 
activity of each individual tube was measured in a gamma scintillation counter (Perkin 
Elmer 1470 Auto-gamma counter) for 1 minute. The standard curve was included to 
determine the concentration of the unknown samples in the tubes. 
 
2.4 DATA ANALYSIS /STATISTICAL ANALYSIS 
All data are expressed as mean ± standard error of the mean (SEM). For multiple 
comparisons, the ANOVA (two-way when appropriate) followed by the Bonferroni 
correction was applied. A p-value of < 0.05 was considered significant. 
The methods used for all of the BP analyses were: Repeated measures analysis of 
variance (ANOVA) using a mixed models estimation method.  Furthermore, descriptive 
statistics were performed by Dr. Justin Harvey (Ph.D. - Mathematical Statistics) at the 
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CHAPTER 3: Results - Using a HFD to elicit high blood pressure in animals to 
study the effects of chronic Buchu water treatment on hypertension.  
(This diet contains 40% fat as well as added sucrose, fructose and cholesterol). 
 
3.1 Biometric Data (parameters) 
The body weight of control (C) rats averaged 377.533 ± 8.01 g. The high fat diet (HFD) 
increased the body weight to 449.467 ± 13.25 (p < 0.0001) over a period of 16 weeks 
(Figure 3-7). Following the 16 weeks on diet, untreated HFD animals were significantly 
bigger than the untreated control animals and we could therefore say that these 
animals were obese (449.467 ± 13.25 vs. 377.533 ± 8.01 g, p < 0.0001).  
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Figure 3-7: Body weight. Shown is the mean body weight (g) after 16 weeks of their respective diets. n = 
15 per group. 
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Table 3-1: Biometric Data - Model 1: HFD Animals. 
Parameters Control Control + B HFD HFD + B 











8.81 ± 0.33 8.56 ± 0.58 
24.35 ± 
2.40*** 
15.39 ± 1.07** 
Fasting Blood 
glucose (mmol/l) 
6.64 ± 0.22 
5.73  ±  
0.16* 





7.16 ± 6.07 11.03 ± 3.90 17.78 ± 11.82 
C-peptide (ng/ml) 523 ± 75.22 328 ± 74.16 
363.3 ± 
63.68 
685 ± 100.8* 
HOMA-IR index 5.48 ± 0.99 2.65 ± 1.09 4.39 ± 0.91 21.45 ± 12.25 
* p < 0.05; HFD vs. HFD + B, C vs. C + B. n = 7 per group 
**p < 0.01; HFD vs. HFD + B. n = 15 per group 
***p < 0.001; C vs. HFD, n = 15 per group 
 
C, control diet; C + B, control diet treated with Buchu water from day 1; HFD, high fat 
diet ; HFD + B, high fat diet treated with Buchu water from day 1; Homeostasis model 
assessment of insulin resistant (HOMA-IR); n = 15 per group for body weight, IP fat 
and fasting blood glucose levels. n = 7 per group for fasting serum insulin levels, C-
peptide levels and the HOMA-IR index. 
3.1.1 Body weight 
The chronic administration of Buchu water significantly reduced body weight gain in 
the HFD group (395.87 ± 13.35 vs. 449.47 ± 13.25 g, p < 0.01) (  
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Table 3-1) (Figure 3-8). The weight gain of the animals on the HFD was 19% vs. only 
4.8% weight gain in the animals on the HFD that also received Buchu water. There 
was no significant difference in weight gain between the control groups. According to 
a two-way ANOVA, the effect of Buchu on body weight was significant with a p < 0.005, 
n = 15 per group. Buchu water treatment for 16 weeks leads to a reduction in weight 
gain in both the control and HFD group however this is only significant in the HFD 
group. 
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Figure 3-8: Body weight. Shown is the BW measured in grams (g) of treated and untreated high fat diet 
(HFD) and control animals after 16 weeks of treatment with Buchu water. n = 15 per group. 
 
3.1.2 Intraperitoneal fat mass 
After 16 weeks on the diet, HFD fed rats had greater amounts of visceral (IP) fat than 
their control counter parts (24.35 ± 2.40 vs. 8.81 ± 0.33 g, p < 0.0001) (  
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Table 3-1) (Figure 3-9). These data indicate that the HFD rats had central obesity.  
Animals on the HFD gained 176.7% visceral fat while animals on the HFD that 
received Buchu water, only gained 76.9% visceral fat. According to a two-way ANOVA, 
the effect of Buchu on IP fat weight was significant with a p < 0.001, n = 15 per group. 
There was no significant difference between the control and the control plus Buchu , 
however there was a significant difference between the HFD group and the HFD group 
with Buchu treatment respectively (24.35 ± 2.40 vs. 15.39 ± 1.07 g, p < 0.0001) (Figure 
3-10).  
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Figure 3-9: Intraperitoneal (IP) Fat. Shown is the IP fat mass measured in grams (g) of the control and high 
fat diet (HFD) animals. n = 15 per group. 
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Figure 3-10: IP fat mass: Shown is the IP fat mass measured in grams (g) of the treated and untreated high 
fat diet (HFD) and control animals after 16 weeks of treatment with Buchu water.  n = 15 per group. 
 
3.1.3 Fasting blood glucose 
Following the 16 weeks on diet, fasting blood glucose levels were significantly higher 
in the untreated control group compared to the treated control group (Figure 3-11). 
There was however no significant difference between control and HFD or the treated 
control and treated HFD animals (Figure 3-11) (  
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Figure 3-11: Fasting blood glucose levels. Shown are the fasting blood glucose levels of treated and 
untreated high fat diet (HFD) and control animals after 16 weeks of treatment with Buchu. n = 15 per group. 
 
3.1.4 Effect on fasting plasma insulin levels 
In Figure 3-12 it is clear that there was no significant difference between the individual 
groups. There was unfortunately a very large standard error in the insulin assay; 
however it shows a trend for higher insulin levels in the obese animals that were 
treated with Buchu water. 
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Figure 3-12: Fasting Serum Insulin levels. Shown are the fasting serum insulin levels of treated and 
untreated high fat diet (HFD) and control animals after 16 weeks of treatment with Buchu. n = 7 per group. 
 
3.1.5 C-peptide levels 
The C-peptide levels of the treated HFD animals was significantly higher than the 
untreated HFD animals (685.17 ± 100.77 vs. 363.29 ± 63.68, p < 0.05) (  
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Figure 3-13: C-peptide levels. Shown are the C-peptide levels determined by an assay of the treated and 
untreated high fat diet (HFD) and control animals after 16 weeks of treatment with Buchu water. n = 6 per 
group. 
3.1.6 Homeostasis model assessment (HOMA) Index 
HOMA insulin resistance (HOMA-IR) index values of treated and untreated HFD and 
control animals after 16 weeks of treatment with Buchu water was calculated. This 
was done to quantify the insulin resistance and beta cell function in the animals. 
Neither the Buchu water nor diet had a significant effect on the HOMA-IR index in the 
different animal groups (Figure 3-14). Values are shown in   
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Figure 3-14: HOMA-IR index values of the treated and untreated HFD and control animals after 16 weeks of 
treatment with Buchu water. n = 7 per group. 
 
3.2 Intraperitoneal glucose tolerance test (IPGTT) 
Figure 3-15 shows that, following the intraperitoneal injection with 1g/kg of sucrose, 
the plasma glucose of both treated and untreated HFD and control animals increased 
similarly from a base line value 6.3 ± 0.18 mmol/l to 6.5 ± 0.9 mmol/l in the first 10 
minutes, before slowly declining to 5.29 ± 0.11 mmol/l after 120 minutes. There was 
no difference in the glucose levels between the four groups at baseline, 30, 60 and 
120 minutes post-glucose load time points. 
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Figure 3-15: The response of plasma glucose to IPGTT of the respective groups. Sucrose was administered 
by IP injection (1g/kg) and the blood glucose levels measured over a 120 min period. n =15 per group. 
 
3.3 Food intake 
Figure 3-16 shows the mean food intake per cage, each with 5 rats, for each group 
during the 16 weeks of the study. There was no difference observed in the amount of 
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Figure 3-16: Food intake. Shown is the food consumption or intake per cage of the treated and untreated 
high fat diet (HFD) and control animals over the 16 weeks of treatment with Buchu water. n = 5 per group. 
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3.4 Metabolic data 
3.4.1 Leptin 
Serum leptin levels were significantly reduced in the treated HFD animals when 
compared to the untreated HFD animals (2274.5 ± 472.2 vs. 4641.63 ± 594.3 pg/ml, 
p < 0.05) (Figure 3-17) while there was no significant difference between the leptin 
levels of the treated and untreated control animals (4425.17 ± 590.84 vs. 3106.0 ± 
535.97 pg/ml) (Figure 3-17). According to a two-way ANOVA, the effect of Buchu 
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Figure 3-17: Leptin. Shown is the leptin level in non-fasting serum of the treated and untreated high fat diet 
(HFD) and control animals after 16 weeks of treatment with Buchu water. n = 5 per group. 
 
  




As can be observed in Figure 3-18, when the amount of adiponectin in the different 
serum samples was compared, there was no significant difference observed between 
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Figure 3-18: Adiponectin. Shown is the adiponectin level in non-fasting serum of the treated and untreated 
high fat diet (HFD) and control animals after 16 weeks of treatment with Buchu water. n = 8 per group. 
 
3.4.3 Tumor necrosis factor (TNF) – alpha 
When the Serum TNF-alpha levels were compared they were the same across all the 
groups (Figure 3-19). There was no significant difference between the control group 
and HFD group (399. 17 ± 34.18 vs. 404.73 ± 25.17 pg/ml) (Figure 3-19). There was 
also no significant difference between the treated HFD and untreated HFD group 
(429.82 ± 17.92 vs. 404.73 ± 25.17 pg/ml) (Figure 3-19). These results argue against 
an inflammatory response in the HFD animals.  
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Figure 3-19: TNF-alpha. Shown are the TNF-alpha values in fasting serum of the treated and untreated high 
fat diet (HFD) and control animals after 16 weeks of treatment with Buchu water. n = 8 per group. 
 
3.4.4 Interleukin (IL)-6 
Figure 3-20 compares the amount of IL-6 in non-fasting serum of each of the individual 
groups. We found no significant difference between of the treated or untreated groups 
as well as when we compared the control group to the HFD group (1075.6 ± 65.83 vs. 
1004.34 ± 37.3 pg/ml) (Figure 3-20). Similar to the TNF-alpha levels, this argues 
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Figure 3-20: Interleukin (IL)-6. Shown is the adiponectin level in non-fasting serum of the treated and 
untreated high fat diet (HFD) and control animals after 16 weeks of treatment with Buchu water. n = 5 per 
group. 
 




Comparing the homocysteine levels in the serum of the different groups, there was no 
significant difference between the treated HFD and untreated HFD as well as between 
the respective controls. However when a two-way ANOVA was conducted it showed 
that the diet did have a significant effect on the homocysteine values (p < 0.001) 
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Figure 3-21: Homocysteine. Shown are the homocysteine levels in non-fasting serum of the treated and 




After 16 weeks of chronic Buchu treatment we observed a significant reduction in the 
aldosterone levels found in the non-fasting serum in the treated HFD animals when 
compared to the untreated HFD (259.77 ± 65.48 vs. 619.88 ± 136.15 pg/ml, p < 0.05) 
(Figure 3-22). There was also a significant difference between the control group and 
the HFD group (119.24 ± 19.08 vs. 619.88±136/15 pg/ml, p < 0.05), when compared 
to each other. Using a two-way ANOVA, the effect of diet on aldosterone was 
significant with a p < 0.001, n = 6 per group. 
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Figure 3-22: Aldosterone. Shown are the aldosterone levels in non-fasting serum of the treated and 
untreated high fat diet (HFD) and control animals after 16 weeks of treatment with Buchu water. n = 6 per 
group. 
 
3.5 Water and Buchu water consumption 
Figure 3-23 shows the mean water or Buchu water consumption per cage containing 
5 animals with 2 cages in each group, during the 16 weeks of the study. The only 
significant difference observed was in the amount of water or consumed by the treated 
control group compared to the untreated control group (168.75 ± 4.919 vs. 143.25 ± 
4.884 ml, p < 0.05) (Figure 3-23). 
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Figure 3-23: Water and Buchu Consumption. Shown is the water consumption or Buchu water intake per 
cage of the treated and untreated high fat diet (HFD) and control animals over the 16 weeks of treatment 
with Buchu water or water respectively. n = 5 per group. 




3.6 Effects on urine production (Urine Output) 
At different times during the 16 weeks of treatment, the urine output of the animals 
was measured over a period of 24h, by keeping them separately in metabolic cages. 
At 8 weeks of treatment, the urine output of animals on the control diet with Buchu 
water was significantly higher when compared to control animals receiving tap water 
(17.55 ± 1.632 vs. 11.33 ± 0.03 ml, p < 0.01) (Figure 3-24) while animals from the HFD 
groups had a significant lower urine output according to a two-way ANOVA (9.53 ± 
1.16 ml, p < 0.0001).  
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Figure 3-24: Urine Output 8 weeks. After 8 weeks on the diet plus Buchu treatment the individual rats were 
placed in metabolic cages as described in the Methods to measure the urine output over a 24 hour period. 
n = 10 per group. 
 
After 16 weeks of treatment, the urine output of the untreated HFD group was 
significantly lower when compared to the control group (4.11 ± 0.9 ml vs. 11.0 ± 0.87 
ml, p < 0.05). In addition, the urine output of the treated HFD animals was significantly 
lower than the treated control animals (5.6 ± 0.98 ml vs. 16.77 ± 1.22 ml, p < 0.001). 
Stellenbosch University  http://scholar.sun.ac.za
79 
 
There was no significant difference between the treated and untreated HFD groups 
but a significantly elevated urine output between the untreated and treated control 
groups were observed (11.0 ± 0.87 ml vs. 16.77 ± 1.22 ml, p < 0.01) (Figure 3-25). In 
addition, according to a two-way ANOVA, the effect of the HFD was highly significant 
(p < 0.0001), indicating water retention in these animals, with or without consumption 
of Buchu water. 
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Figure 3-25: Urine Output. After the 16 week diet plus Buchu treatment the individual rats were placed in 
metabolic cages as described in the Methods section to measure the urine output over a 24 hour period. n 
= 10 per group. 
 
3.7 Antihypertensive effects of Buchu administration:  
3.7.1 Systolic BP 
We used the HFD to cause obesity and induce HTN in the animals. As shown in Figure 
3-26 the BP of the five groups of animals was not different at the commencement of 
the study. After only 4 weeks of the HFD, the onset of HTN can already be seen (Figure 
3-26 & Figure 3-27). These animals then developed a significant elevation of their BP 
within 8 weeks (HFD 147.21 ± 5.0 vs. Control 125.01 ± 3.1 mmHg, p < 0.0001, n = 10 
animals per group). We either pre-treated the animals with Buchu water, starting at 
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day one, or we allowed the animals to become severely hypertensive until a later stage 
(week 8) and then started the Buchu treatment. 
As can be seen in Figure 3-26 Buchu water consumption prevented the development 
of systolic HTN when given in conjunction with the HFD when compared to the HFD 
alone (125.94 ± 12.01 vs. 157.11 ± 8.73 mmHg, p < 0.0001). Buchu water treatment 
did not affect the BP of the animals on the control diet (122.44 ± 8.2 mmHg). In 
addition, treatment of already hypertensive animals (week 8) with Buchu water 
normalised their BP within two weeks from 153.1 ± 8.01 to 122.51 ± 10.73 mmHg 
(Figure 3-26). Buchu presents both preventative measures and treatment properties 
for systolic HTN. 
 
Figure 3-26: Systolic Blood pressure (SBP). Rats were fed a HFD for 16 weeks and blood pressure were 
monitored every two weeks as described in Methods. Time is in weeks. Every 1 time unit = 2 weeks; 0-2 
weeks conditioning/training. 3-10 weeks is the treatment and diet period. n = 10 per group. 
 
Group*Time; LS Means
Current effect: F(40, 419)=5.7781, p=0.0000
Type III decomposition
Vertical bars denote 0.95 confidence intervals
 Group
 Diet = Control; Buchu = None
 Group
 Diet = Control; Buchu = Day 1
 Group
 Diet = HF; Buchu = None
 Group
 Diet = HF; Buchu = Day 1
 Group
 Diet = HF; Buchu = Week 8
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3.7.2 Diastolic BP 
After 16 weeks on diet, there was a significant difference in the DBP when comparing 
the different groups of animals. The control group presented with significant lower DBP 
when compared to the HFD group (82.27 ± 1.40 vs. 102.56 ± 1.39 mmHg; p < 0.0001) 
(Figure 3-27).  It is clear that these HFD animals were hypertensive whereas the 
control animals remained normotensive. There was no significant difference between 
the untreated or treated control animals. The HFD animals treated with Buchu water 
from day one did not develop any increase in diastolic BP over the 16-week period 
while animals treated from week 8, within two weeks, showed a significant decrease 
in BP when compared to the HFD group (86.25 ± 13.1 and 77.73 ± 9.08 vs. 103.49 ± 
13.73 mmHg) (Figure 3-27). Buchu presents both preventative measures and 
treatment properties for diastolic HTN. 
 
Figure 3-27: Diastolic Blood pressure (DBP). Rats were fed a HFD for 16 weeks and blood pressure were 
monitored every two weeks as described in Methods. Time is in weeks. Every 1 time unit = 2 weeks; 0 -2 
weeks conditioning/training. 3-10 weeks is the treatment and diet period.  n = 10 per group. 
 
Group*Time; LS Means
Current effect: F(40, 419)=4.4808, p=.00000
Type III decomposition
Vertical bars denote 0.95 confidence intervals
 Group
 Diet = Control; Buchu = None
 Group
 Diet = Control; Buchu = Day 1
 Group
 Diet = HF; Buchu = None
 Group
 Diet = HF; Buchu = Day 1
 Group
 Diet = HF; Buchu = Week 8
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3.8 Aorta Rings 
To investigate whether the endothelial function played any role in the observed 
changes in BP, aortic rings were harvested as described in Materials and Methods.  
They were mounted in an organ bath, stabilized and their intactness tested as 
described in the Methods section. The aortic rings contracted with the addition of PE 
(10-6 M) and the contraction reached a plateau in 5-10 minutes. The mean tensions 
attained were 1.8 ± 0.48 g and 1.9 ± 0.35 g for control and HFD rats, respectively. The 
maximum relaxation in response to ACh in control and HFD rats was 50.03 ± 5.29 and 
47.58 ± 4.73% of the contractile response to PE, respectively (Figure 3-28 &   
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Table 3-2). Accordingly to the endothelium dependent relaxation to ACh there was no 
significant difference between the control animals and HFD animals, as well as the 
respective treated groups. Therefore we did not detect that Buchu water treatment had 
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HFD + Buchu Day 1


































Figure 3-28: Aortic rings studies. Shown is the comparison of relaxation response to acetylcholine (ACh) 
in aortic rings of Buchu water treated and untreated control and HFD rats. Relaxation is expressed as 
percentage of contraction to phenylephrine (PE) and shown as mean ± SE. n = 5 per group. 
  
Stellenbosch University  http://scholar.sun.ac.za
84 
 
Table 3-2: Aorta rings studies relaxation. Shown is the relaxation response of aorta rings to acetylcholine 






HFD +   
Buchu 
Day 1 
30 nM ACh 94.04  ± 0.84  94.09 ± 1.24 
92.00 ± 
2.25 
90.67 ± 3.82 
100 nM ACh 83.06 ± 2.25 82.22 ± 3.22 
77.48 ± 
5.81 
78.46 ± 5.67 
300 nM ACh 68.84 ± 6.02 70.80 ± 4.47 
67.60 ± 
6.45 
64.29 ± 6.01 
1 µM ACh 58.57 ± 8.00 58.86 ± 5.11 
59.20 ± 
6.60 
53.99 ± 5.99 
10 µM ACh 49.97 ± 8.58 47. 85 ± 4.89 
52.42 ± 
5.62 
45.65 ± 6.36 
Total relaxation 50.03 ± 5.29 52.15 ± 4.73 
47.58 ± 
4.73 
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3.9 Expression and phosphorylation of proteins (16 weeks) 
Expression and activation of proteins in the aorta’s between Buchu treated and 
untreated control and HFD animals. 
3.9.1 Protein kinase B (PKB/Akt) protein  
3.9.1.1 Total PKB/Akt protein 
We evaluated the total protein content of PKB/Akt in aortas from the different groups 
of animals (Figure 3-29). Under basal conditions, there was no significant difference 
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Figure 3-29: Total PKB/Akt. Shown is the total PKB/Akt expression in aortas of both the control and diet 
groups with and without treatment. n = 3 per group. 
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3.9.1.2 Phosphorylated PKB/Akt protein 
At basal levels, there was no stimulation by any substance to activate any of the 
protective protein pathways (PI3K-Akt pathway) in the aortas. Therefore we did not 
observe any phosphorylated PKB/Akt protein in the aorta tissue samples. 
3.9.2 AMPK protein 



































Figure 3-30: Total AMPK. Show is the total AMPK expression in the aorta’s of both the control and diet 
groups after 16 weeks of treatment.  n = 3 per group. 
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Figure 3-31: Phosphorylated AMPK. Shown are the levels of phosphorylated AMPK in the aortas of the diet 
and treated groups. n = 3 per group. 
To evaluate the effect of NO (a potent vasodilator in the body) on BP we measured 
the expression of key proteins leading to the upregulation of eNOS the protein 
responsible for the synthesis of NO. There was no significance in the total AMPK and 
phospho-AMPK found between the diet groups or the treated groups. 
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3.9.3 eNOS protein 
3.9.3.1 Total eNOS 
We evaluated the total protein content of eNOS in aortas from the different groups of 
animals (Figure 3-32). Under basal conditions, there was no significant difference in 
the expression of eNOS between the untreated and treated animals, however there 
was a significant difference found between the control and HFD groups after 16 weeks 
































Figure 3-32: Total eNOS. Shown are the levels of total eNOS in the aortas of the diet and treated groups. n 
= 4 per group. 
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CHAPTER 4: Results - Obese, insulin resistant animals without elevated blood 
pressure. 
4.1 Cardiovascular effects of Buchu water treatment 
To determine the cardiovascular effects of Buchu water treatment, we also made use 
of a well-established rat model of hyperphagia-induced central obesity (DIO) 
(Pickavance et al., 1999). The animals on this diet are pre-diabetic but do not develop 
high BP which would be a confounding effect on the cardiovascular system.   
 
4.2 Body weights 
According to a two-way ANOVA, the effect of Buchu water on body weight was 
significant with a p = 0.03. Therefore the chronic administration of Buchu water 
significantly reduced body weight gain in both the DIO (408.13 ± 11.31 vs. 355.13 ± 
30.08 g) (Figure 4-33) and control groups (375.13 ± 17.21 vs. 361.5 ± 13.93) (Figure 
4-33).  
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Figure 4-33: Body weight. Shown is the BW measured in grams (g) of treated and untreated diet induced 
obesity (DIO) and control animals after 16 weeks of treatment with Buchu water. n = 10 per group. 
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4.3 IP fat mass 
The rats were 16 weeks on the diet and treatment with no significant difference 
between the amounts of visceral fat in either the DIO animals (19.46 ± 2.38 vs. 16.82 
± 1.90 g) (Figure 4-34) or the control animals (13.33 ± 2.15 vs. 9.69 ± 1.68 g) (Figure 
4-34). However according to a two-way ANOVA analysis, the effect of the diet on IP 























Figure 4-34: Intra-peritoneal (IP) fat mass. Shown is the IP fat measured in grams (g) of treated and 
untreated diet induced obesity (DIO) and control animals after 16 weeks of treatment with Buchu water. n 
= 8 per group. 
 
It was demonstrated by B Huisamen et al, unpublished result that the hearts of these 
animals were protected from ischaemia/reperfusion injury by ingesting Buchu water 
as evidenced by smaller infarct size development after regional ischaemia followed by 
120 min reperfusion. This was evident for both the treated controls vs. their respective 
untreated controls (28.75 ± 1.48 vs. 35.24 ± 1.47%, p < 0.05) (Figure 4-35) and the 
treated DIO animals vs. the untreated DIO animals (39.11 ± 2.56 vs. 48.63 ± 2.21%, 
p < 0.01) (Figure 4-35).  According to a two-way ANOVA, the effect of Buchu on infarct 
size was highly significant with a p < 0.0002, n = 8 per group. There was also a 
significant difference in the infarct size between the control and DIO animals with the 
infarct size of the DIO animals being significantly larger than those of the control 
animals (48.63 ± 2.21 vs.35.24 ± 1.47%, p < 0.01) (Figure 4-35).   
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Figure 4-35: Infarct sizes - DIO model. Shown is the infarct size (% of area at risk) of the isolated hearts, 
from the DIO and control rats perfused ex vivo in working heart mode after they were treated for 16 weeks 
in their respective groups. n = 8 per group. 
 
4.4 Glucose uptake (2DG) in isolated cardiac myocytes 
On an organ level, we investigated if the insulin sensitivity of cardiomyocytes were 
improved by ingestion of Buchu water, by measuring the glucose uptake in isolated 
cardiomyocytes (CM). A two-way ANOVA showed the overall glucose uptake of 
isolated cardiomyocytes at basal level, to be significantly increased when animals 
were pre-treated with Buchu water (p < 0.05) (Figure 4-36). 
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Figure 4-36: Cardiomyocyte glucose uptake. Shown is the DG uptake by cardiomyocytes from the DIO and 
control rat groups at basal levels with no stimulation of insulin. Data expressed as mean ± SED. n = 6 per 
group. 
The glucose uptake by cardiomyocytes prepared from all the different experimental 
groups did however not indicate a significant difference when they were stimulated 
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Figure 4-37: Cardiomyocyte glucose uptake all the groups. Shown is the DG uptake by cardiomyocytes 
from all the specific rat groups at basal levels and after stimulation with 1 nM, 10 nM and 100 nM insulin. 
The insulin sensitivity of the cardiomyocytes was determined by means of measuring the ability of cell to 
accumulate radioactive labelled deoxyglucose before and after the stimulation of insulin. Data expressed 
as mean ± SED. n = 6 per group. 
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CHAPTER 5: DISCUSSION 
Obesity is a vastly widespread metabolic disorder that has reached epidemic 
proportions all over the world (Deitel, 2003; Stevens et al., 2012) and South Africa is 
no exception to this. Recently it was shown that 29% of men and 56% of women in 
South Africa are overweight or obese (Puoane et al., 2002). The increasing prevalence 
of obesity is mostly due to life style changes (inactivity and HFD) and, together with 
the associated rise in BP, can result in morbidity. Both obesity and HTN are important 
risk factors for CVD, the number one cause of death globally (Kelly et al., 2012; Lim 
et al., 2012; Murray et al., 2012). 
 
In an attempt to control these disease states, individuals require effective medication 
which can be used in conjunction with healthy life style changes. The use of herbal 
based therapies is currently strongly encouraged, as they offer potentially cost-
effective and readily accessible management. However, scientific validation of their 
effects is needed. In Africa, herbal remedies and folk medicine have been used for 
centuries by the ‘Khoisan’ and other indigenous peoples to treat various ailments. It 
was also the Khoisan who introduced Buchu to the western colonist. Buchu is a plant 
native to South Africa and is perhaps the best known aromatic medicinal herb. Buchu 
water is the by-product of the extraction of Buchu oil. The latter is mainly isolated from 
the leaves of Agathosma crenulata and Agathosma betulina, both endemic to the 
mountains of the Western Cape in South Africa. The oil is used as a flavour enhancer 
in the perfume and food industries. The aqueous solution is currently marketed as a 
herbal remedy to treat various ailments e.g., urinary infections, rheumatism, arthritis 
and obesity. It is also advocated as an effective treatment of HTN. However these are 
only anecdotal claims with no scientific evidence. 
 
This study therefore aimed to investigate these claims in different animal models, 
namely a HFD rat model in which the animals become obese and hypertensive. In 
addition we investigated the cardioprotective properties of this substance in isolated 
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cardiomyocytes prepared from rats fed a diet resulting in hyperphagia and obesity. 
However, these animals do not become hypertensive. 
 
5.1 Overview of our findings 
The major findings of the present study were as follows: i) Buchu water ingestion 
improved some indices of glucose tolerance and whole body glucose homeostasis; ii) 
Buchu water selectively reduced visceral fat depots when given from the onset of the 
HFD; iii) Buchu water prevented HTN when given at the onset of obesity in rats and 
iv) rapidly decreased systolic and diastolic blood pressures in already obese, 
hypertensive rats. v) Buchu water treatment elevated basal myocardial glucose uptake 
in correlation with cardioprotection. 
 
5.1.1 Primary aim of present study 
The primary aim of the current study was to evaluate the ability of Buchu water to 
prevent HTN induced by obesity in rats. The results are clearly demonstrated in 
animals maintained on a HFD that caused a sustained increase in BP while Buchu 
treatment not only prevented HTN induced by obesity, but also surprisingly, caused a 
large and rapid decrease in body weight and intraperitoneal fat accumulation. In 
addition, Buchu water normalised the BP of already hypertensive animals. 
 
5.2 DISCUSSION PART 1 – Using a HFD to elicit high blood pressure in animals 
to study the effects of chronic Buchu water treatment on hypertension 
The first rat model was aimed at inducing obesity and HTN to investigate the 
antihypertensive properties of Buchu water. A modification of a previously published 
HFD was used (K. Srinivasan, Viswanad, Asrat, Kaul, & Ramarao, 2005). These 
animals developed HTN within a four-week period (Figure 3-26 & Figure 3-27). Not 
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only was Buchu water treatment able to prevent the development of HTN when given 
in conjunction with the HFD, but it normalised elevated BP within two weeks. 
 
5.2.1 Effect of Buchu water treatment on the biometric parameters (body 
weight, IP fat and food intake) 
BODY WEIGHT AND BUCHU TREATMENT 
Fat enriched diets have been used for decades to model obesity (Budohoski et al., 
1993). The relative fat fraction in these diets varies between 20% and 60% and the 
basic fat component differs between animal-derived fats or plant oils. It is well 
documented that, when energy intake exceeds energy expenditure, there is excess 
storage of energy in the form of fat (adipose tissue). In the present study the animals 
were placed on a diet consisting of a 40% fat component which did not replace the 
carbohydrate component, but was added fat as well as added sucrose, fructose and 
cholesterol to a standard rodent chow. Thus the animals ingested food with dense 
calorie content and therefore became obese. These animals gained more body weight 
when compared to their age matched control animals on normal rat chow (Figure 3-
7). Obesity induction is most effective when the diet is started at a young age as was 
done in the present study (Peckham, Entenman, & Carroll, 1962). Prolonged feeding 
of fat enriched diets induces an increase in body weight in a range between 10% and 
20%, was concluded in a review that compared various high fat diets that model the 
metabolic disorder of human obesity in rodents (Buettner, Scholmerich, & Bollheimer, 
2007). In our present study the percentage of weight gain between the untreated HFD 
and control group corresponds with this (19%). There is a close relationship between 
obesity and HTN and this has been documented in the literature (El-Atat et al., 2003; 
Hall, 2000; Hall et al., 2003; Morse et al., 2005). Experimental studies have shown 
that weight gain leads to increases in BP, whereas clinical studies indicated weight 
loss leads to a reduction in BP in hypertensive patients (Berchtold et al., 1981; 
Berchtold et al., 1982; He et al., 2000). Subsequent studies have shown that excess 
weight gain can be used as a predictor for the development of HTN (Hall, 2000; Hall 
et al., 2001). This coincides with the present study, which showed that the HFD group 
gained excessive weight on the HFD which led to raised BP levels during the study. 
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These obese animals became HTN after only four weeks on the HFD, whereas the 
control group gained body weight more naturally with age on the SRC. Their BP stayed 
constant during the study (normotensive).  We administered Buchu water to a HFD 
group to see if we can prevent the onset of HTN in these animals on a HFD. Although 
there was slightly more weight gain than the control group, this did not affect the BP. 
These animals were also normotensive at the end of the 16 weeks of treatment. This 
group represent normotensive individuals in our society that follow an unhealthy HFD. 
The results suggested that with Buchu water treatment, excess weight gain and the 
onset of HTN may be prevented in these individuals. 
IP FAT AND BUCHU WATER TREATMENT 
When comparing the body weight of the animals it was clear that the increase in weight 
was due to an increase in visceral fat content (Figure 3-10). High fat diets produce a 
significant increase in body fat content which depends on the amount of fat content in 
the food and the duration of feeding. Numerous studies showed that excess abdominal 
(android or upper body) obesity increase the risk for HTN (Sironi et al., 2004) and 
ultimately CVDs. In addition, a study done on obese, hypertensive women has also 
pointed out that a decrease in intra-abdominal visceral fat reduces BP (Kanai et al., 
1996). The current study clearly demonstrated an increase in body weight (Figure 3-
8) and fat mass (Figure 3-10) after rats were exposed to a HFD for 16 weeks. The 
untreated HFD group which were hypertensive as a result of the excess body weight, 
also had a significant increase in visceral fat content when compared to their 
respective controls. The visceral fat content of the HFD group nearly increased three-
fold.  
This excess adipose tissue is a result of additional FFA being deposited in mature 
adipocytes (hypertrophy) or the formation of new adipocytes from preadipocytes 
(hyperplasia) (Faust et al., 1978). The expansion of IP fat in obesity is mostly due to 
an increase in size of the mature adipocytes (Kim et al., 2007). The low grade 
inflammatory state associated with obesity leads to an increase in pro-inflammatory 
cytokines produced by immune cells like macrophages in adipose tissue and the liver. 
These pro-inflammatory cytokines directly impair the formation of new small 
adipocytes from preadipocytes but does allow the larger mature adipocytes to expand 
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even further (Lacasa et al., 2007). In our study, animals that consumed a HFD but 
ingested Buchu water in conjunction with this, gained less weight when compared to 
the untreated HFD animals and also had a smaller amount of accumulated visceral fat 
content. This may be why we did not see an increase in BP despite the HFD. 
FOOD INTAKE 
From previous studies we know that an increase in food consumption leads to an 
increase in circulating macronutrients in body. This is associated with weight gain and 
large amounts of visceral fat depots. Conversely, a decrease in food consumption is 
associated with weight loss (Harris, Kasser, & Martin, 1986; Hill, Latiff, & DiGirolamo, 
1985).  We therefore determined the food consumption of the animals over the 16 
week period. Results indicated that the food consumption per cage containing five 
animals, per week, did not differ in any of the groups (Figure 3-16). Although the caloric 
content of the two diets did differ (thus accounting for the increased weight gain 
between the control and HFD groups) the amount of food consumed by the different 
groups of animals did not differ. The decrease in body weight and IP fat weight in both 
Buchu treated groups are thus not associated with a decrease in food intake.  
Interestingly, clinical studies on the effects of antihypertensive medications such as 
ACEI and ARBs also indicated a reduction in IP fat (He et al., 2000; MacMahon et al., 
1990; Neal et al., 2000). A study done with Telmisartan, an angiotensinogen II type 
receptor blocker, by Shimabukuro et al. (2007), reported a reduction in BP together 
with a decrease in visceral fat content (Shimabukuro, Tanaka, & Shimabukuro, 2007). 
Another study done on mice also showed weight loss with the use of Captopril, another 
ACEI (Weisinger et al., 2009). These analogies suggest that Buchu water may exert 
its effects by interacting with a mechanism in the RAAS. This may lead to a reduction 
in IP fat and in turn prevent the increase in BP.  
Other factors that may have led to a reduction in body weight may have been different 
metabolic rates and improved HFD tolerance. Furthermore, the decrease in body 
weight gain may also have been due to a reduced ability to extract energy from the 
food (Kristensen et al., 2013). 
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5.2.2 Effect of Buchu water treatment on blood glucose, insulin levels and 
insulin sensitivity 
BLOOD GLUCOSE 
Fasting blood glucose levels have been reported in various HFD’s as normoglycaemia, 
slight hyperglycaemia and pre-diabetic. It seems to be dependent on the type and 
contents of the diet. Glucose is a carbohydrate and is one of the main energy sources 
for metabolism in mammalian cells. Our data showed that Buchu water treatment for 
16 weeks decreased the fasting blood glucose levels in the treated control group 
(Figure 3-11). In contrast to this, no effect was observed in the treated HFD group. 
The range of fasting blood glucose across all the groups was within the normal range 
(≤ 6.5 mmol/l), therefore normoglycaemic. This is rather important since several first 
line regiments for the management of uncomplicated HTN have clearly exhibited 
distinctive adverse effects. One of these is that, with obesity associated HTN, there is 
an increased rate of diabetes being reported (Taylor, Hu, & Curhan, 2006). The 
antihypertensive agents can affect the glucose homeostasis, especially with thiazide 
diuretics and BBs (Gress, Nieto, Shahar, Wofford, & Brancati, 2000a; Helgeland et al., 
1984; Kostis et al., 2005). Thiazide diuretics have been found to alter glucose control 
via hepatic insulin resistance, resulting in continued hepatic glucose production 
despite rising glucose and insulin levels (Harper et al., 1994; Hunter et al., 1998), 
whereas BBs have been found to inhibit insulin release from the pancreatic beta cells 
(Gress, Nieto, Shahar, Wofford, & Brancati, 2000b). On the other hand, first line 
antihypertensive agents such as ACEIs, CCBs or ARBs have not been reported to 
disrupt the glucose homeostasis in the body. Calcium channel blockers have exhibited 
minor effects on glucose metabolism (Sowers, 1997) whereas ACEIs and ARBs may 
actually possess beneficial effects (Hansson et al., 1999a). These observations may 
be of utmost importance since significant glycaemic effects caused by 
antihypertensive medication can accelerate the risk of developing CVD (Dunder, Lind, 
Zethelius, Berglund, & Lithell, 2003). Therefore by comparing our results with these 
studies, one would not expect the glucose homeostasis to be disrupted during chronic 
Buchu water treatment. 
INSULIN 
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Ever since obesity and HTN have been associated with each other, they have been 
assumed to be linked to insulin resistance and hyperinsulinemia (Hall et al., 1989; Hall, 
1993). Chronically elevated insulin is a marker of metabolic dysfunction, and typically 
accompanies high fat mass, poor glucose tolerance (pre-diabetes) and blood lipid 
abnormalities. In the present study our data did not find that the insulin levels were 
elevated in the treated or untreated control groups (Figure 3-12,   
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Table 3-1). This is as would be expected, since these animals were representing 
healthy individuals which were able to maintain an adequate balance in the amount of 
FFA and glucose in their blood circulation during a fasting state of metabolism. The 
untreated HFD animals which were classified as obese and hypertensive also did not 
have elevated levels of insulin (Figure 3-12). The results clearly indicate that the 
animals on the HFD were not insulin resistant but still had high BP. Our study confirms 
that, in our model, there is no connection between HTN and hyperinsulinemia, as 
previously reported by Hall et al. (1989) when he infused dogs with excess insulin for 
several weeks to see if hyperinsulinemia can cause a response in BP (Hall et al., 
1989). It is often expected that obese individuals have elevated insulin levels 
(DeFronzo & Ferrannini, 1991; Reaven, 1988). However, whether obesity precedes or 
follows hyperinsulinemia is uncertain (S. R. Srinivasan, Myers, & Berenson, 1999). 
Although there was no clear significance between the insulin values of the different 
groups in our study (because of the large standard error in the insulin assay), 
nonetheless it does show a trend that the insulin levels were elevated in the obese 
animals that were treated with Buchu water (Figure 3-12). This assay was performed 
on fasting blood and it seems as if the levels varied greatly at this level. This 
observation warrants further investigation. 
C-PEPTIDE LEVELS & INSULIN SENSITIVITY 
Insulin sensitivity describes how sensitive the whole body is to the effects of insulin. 
An insulin sensitive individual will require low levels of insulin to elicit a response to 
lower blood glucose where as someone with low insulin sensitivity will require higher 
levels of insulin to maintain glycaemia. Intraperitoneal glucose tolerance curves 
generated on all the animals in the current study showed that the HFD animals did not 
present with whole-body insulin resistance nor were any effect of the Buchu water on 
this parameter observed (Figure 3-15). 
In addition, insulin sensitivity was expressed as the HOMA index which is a non-
invasive calculation of insulin sensitivity using fasting insulin and glucose levels. Again, 
no evidence of insulin resistance was observed in the control or control treated animals 
(Figure 3-14). A higher level of insulin was observed in the HFD animals treated with 
Buchu water. It may be that Buchu treatment interacted with the pancreas resulting in 
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insulin secretion. This is supported by an increase of plasma C-peptide levels in the 
treated HFD animals. However, an increase in C-peptide levels was not observed in 
the control animals consuming Buchu water. The possible pancreatic effects of Buchu 
water warrants further investigation. 
 
5.3 Adipokines 
Adipose tissue is no longer seen as a just an energy reservoir for FFA and triglycerides 
but rather as a dynamic tissue which modulates energy metabolism via the secretion 
of circulating adipocytokines (Trayhurn & Wood, 2005). Adipose tissue has also been 
described as an active endocrine organ by Kershaw et al. (2004) in his review 
(Kershaw & Flier, 2004).   
Leptin is an adipokine predominantly secreted by adipocytes and acts on the 
hypothalamus in the brain (Van Harmelen et al., 1998). It can therefore cross the blood 
brain barrier (Bouret, 2008). Its physiological function is to control appetite and 
regulate energy homeostasis through a negative feedback loop in times of food 
abundance, to prevent obesity (Hall et al., 2001). Leptin is therefore associated with 
body weight control. The amount of leptin present in the circulation is proportional to 
the amount of fat mass (Handjieva-Darlenska & Boyadjieva, 2009). An obese 
individual is prone to develop resistance against the central effects of leptin. 
Resistance to leptin refers to an inadequate response because of a decreased 
sensitivity to the effects that leptin exert at normal physiological or increased 
pathophysiological levels (Lin, Thomas, Storlien, & Huang, 2000). This is due to the 
overstimulation by circulating leptin because of increased secretion by adipose tissue. 
Most importantly, the serum leptin levels in the present study showed an expression 
pattern co-inciding with the size of the fat depots. Chronic Buchu treatment decreased 
the leptin levels of the obese animals below that of the control groups (Figure 3-17;   
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Table 3-1). As leptin levels are closely associated with insulin resistance, this is quite 
an important result. The adipose tissue was also greatly reduced in the treated obese 
animals (Figure 3-10). These data suggest that the reduction in leptin levels was in 
part due to less adipose tissue being present in the treated HFD animals since the 
amount of leptin found in the circulation is proportional to the amount of fat mass 
(Handjieva-Darlenska & Boyadjieva, 2009). The overall effect of Buchu treatment was 
significant as indicated by two-way ANOVA analysis. These findings are contradictory 
since low leptin levels are known to stimulate appetite and we observed no difference 
in the amount of food consumed by the different animal groups (Figure 3-16). This 
suggests that Buchu water treatment did not decrease the leptin levels nor has any 
effect on the amount of food being consumed but rather affected the adipose tissue 
and thus caused the reduction in the leptin levels that we observed in the treated HFD 
animals. 
Adiponectin plays an important role in the development of insulin resistance and 
atherosclerosis, both risk factors for CVD.  Adiponectin is usually found in high 
concentrations circulating in the blood in healthy individuals. In obese individuals, 
lower concentrations of adiponectin have been reported in the circulation, associated 
with increasing development of insulin resistance. In humans, adiponectin levels are 
found to be inversely correlated with the percentage of body fat (Gavrila et al., 2003). 
Adipose tissue is thus a negative predictor of adiponectin (Gavrila et al., 2003). 
Adiponectin is also said to decrease prior to the onset of T2D. Adiponectin 
administration is associated with decreased levels of plasma glucose and increasing 
insulin sensitivity. A review by Silva et al. (2011) considered evidence of studies that 
investigated the effect of diet on adiponectin and the conclusion was that dietary 
management can be a therapeutic option to increase adiponectin levels, especially 
with a low calorie diet (Silva, de Almeida, & Feoli, 2011). However, in our study the 
adiponectin levels (Figure 3-18) were not increased, despite the loss in intraperitoneal 
fat (Figure 3-10). Disappointingly so, as this would have explained some of the 
cardioprotective effects observed in the DIO model (Figure 4-35). This negative result 
in our study may correlate well with a study done in humans where it was found that 
adiponectin levels were inversely correlated with fasting insulin levels (Park et al., 
2004). In our study, the treated HFD animals had an unexpected trend towards higher 
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fasting insulin concentrations (Figure 3-12) and lower adiponectin levels where as the 
opposite were true for the HFD group (Figure 3-18). 
 
5.4 Anti-inflammatory activity of Buchu water treatment 
TNF-alpha & IL-6 
Inflammation plays an important role in vascular biology. Therefore in recent years 
there has been thought to exist a close association between inflammation and HTN. 
This is based on studies that showed an increase in inflammatory molecules 
circulating in the blood of hypertensive patients (Bautista et al., 2001; Bautista, 
Atwood, O'Malley, & Taylor, 2004; Bautista, Vera, Arenas, & Gamarra, 2005; Sung et 
al., 2003). Conversely, other studies showed that there is no association between IL-
6 and high BP (Chae, Lee, Rifai, & Ridker, 2001; Rifai, Joubran, Yu, Asmi, & Jouma, 
1999). Inflammation has not only been thought to be associated with HTN but also 
with obesity. The large amount of VAT is not only responsible for its metabolic activity 
through the secretion of adipokines but also produces proinflammatory cytokines such 
as IL-6. Inflammatory markers such as IL-6 and TNF-alpha are used in the prediction 
of future complications that result in CVD (Ridker et al., 1997; Ridker et al., 2000; 
Ridker, 2013). Treatments that can modify these levels of proinflammatory cytokines 
can prevent the risk of myocardial infarction and strokes. The literature describes 
Buchu as a medicinal herb having anti-inflammatory properties (Moolla & Viljoen, 
2008). Unfortunately our HFD model did not show signs of either elevated TNF-alpha 
(Figure 3-19) or IL-6 (Figure 3-20). Thus no low-grade or chronic inflammation could 
be detected in the plasma. The Buchu water treatment did not affect these levels 
either. Therefore we could not really detect any anti-inflammatory response by 
analysing the serum. It is still possible that these cytokines were elevated in the fat 
tissue (Evans et al., 2011), but this was not measured in the current study. In future, 
a model with a clear inflammatory response may also be used to investigate whether 
Buchu treatment will have systemic anti-inflammatory effects.  
HOMOCYSTEINE 
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Homocysteine is a metabolite of the amino acid methionine and has been linked to an 
elevated risk of vascular disease (Stead, Brosnan, & Brosnan, 2000). Hypertension 
seldom occurs in isolation from other cardiovascular risk factors but HTN appears to 
be metabolically connected to plasma homocysteine levels (Rodrigo et al., 2003). 
Homocysteine levels have been shown to be associated with BP, especially SBP (U. 
Lim & Cassano, 2002; Malinow et al., 1995). A study done on human subjects showed 
that there is an interrelationship between homocysteine, obesity and HTN. They 
observed a prevalence of hyperhomocysteinemia in hypertensive individuals 
compared to normotensive individuals (Karatela & Sainani, 2009). This corresponds 
with our present study. Our results indicated elevated levels of homocysteine in the 
HFD animals (Figure 3-21). This is an effect correlated with the obesity in these 
animals and signifies a relationship between obesity and homocysteine. However, the 
incidence of HTN did not seem to be related to this increased level of homocysteine, 
since the treated HFD group who were now not hypertensive, still had elevated levels 
of homocysteine. These results are rather contradictory but clearly show that Buchu 
water treatment had no significant effect on the homocysteine levels. 
Data about the effects of antihypertensive drugs on homocysteine levels are scarce, 
but they do exist and they report an absence of change or decrease in homocysteine 
levels as well as an increase (Atar et al., 2005; Korkmaz et al., 2003; Westphal, 
Rading, Luley, & Dierkes, 2003). An increased level of homocysteine is an unwanted 
side effect since hyperhomocysteinemia is seen as a risk factor for CVD (Clarke et al., 
1991; Wald, Law, & Morris, 2002). However, lowering BP with anti-hypertensive 
treatment is more important than normalizing homocysteine levels. While detection of 
high levels of homocysteine has been linked to CVD, lowering homocysteine levels 
may not improve outcomes (Bonaa et al., 2006; Marti-Carvajal, Sola, Lathyris, & 
Salanti, 2009). 
5.5 Blood pressure 
Feeding the rats a HFD resulted in severe HTN in conjunction with obesity as co-
inciding effects. Significant HTN developed within 4 weeks after the change in diet 
started (Figure 3-26 & Figure 3-27).  
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Not only did Buchu water prevent the development of HTN in the HFD group treated 
from day one, but it was also able to treat HTN when animals were allowed to develop 
HTN for a period of 8 weeks. Within two weeks, the BP of these animals went from 
hypertensive to normotensive (Figure 3-26 & Figure 3-27). Buchu water treatment 
therefore restored the BP to normal. The reduction in BP was seen only in the obese 
animals since no reduction in BP was noticed in the treated control group. 
Although the mechanisms of obesity induced HTN are not fully understood, we can 
speculate on the pathophysiological effects that are associated with the HFD that can 
lead to HTN. In obesity there are three changes that occur that can alter the body’s 
physiology and lead to increased BP; i) increased sympathetic stimulation (de Kloet et 
al., 2013), ii) synthesis of adipokines by the excess visceral adipose tissue depots in 
the abdomen and iii) hemodynamic alterations. It is described in the literature that the 
SNS contributes to the homeostasis of the body (Simonds & Cowley, 2013). In obesity 
there are several mechanisms and mediators causing over activity of the SNS leading 
to increased adrenergic sympathetic stimulation. A study done by Wofford (2004) 
showed that, by blocking alpha- and beta-adrenergic receptors in hypertensive 
individuals, it reduced BP significantly when compared to lean hypertensive individuals 
(Wofford & Hall, 2004), indicating that the SNS is stimulated during obesity and does 
play a role in the increased BP. Another contributing factor that can lead to increased 
SNS activation is increased leptin levels. As previously stated, Leptin is an adipokine 
predominantly secreted by adipocytes and acts on the hypothalamus in the brain (Van 
Harmelen et al., 1998). Although the HFD did not significantly elevate leptin levels in 
the animals, Buchu treatment for 16 weeks reduced the leptin levels in the treated 
HFD and control groups (Figure 3-17) this may have contributed in an independent 
manner to the decrease in BP observed in the treated HFD group. However, the 
current study did not evaluate SNS activity.  
Rodent and human adipose tissue synthesizes all the components of the RAAS 
(Karlsson et al., 1998) which may be another mechanism that contributes to obesity 
induced HTN. Buchu water treatment in the present study caused a reduction in weight 
gain between the treated and untreated groups and had significant effect on the body 
weight of the animals (Figure 3-8). The reduction in body weight was due to a decrease 
in visceral fat content (Figure 3-10) and this by itself, may account for the normotensive 
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BP readings. Besides the effect that adipose tissue RAAS exerts on BP it also helps 
with the accumulation of fat. Angiotensin II binds to AT1 receptors expressed in 
adipose tissue and stimulates lipogenesis, inducing adipocyte differentiation and 
growth (Engeli et al., 1999). Administrating an ACEI (an antihypertensive drug) such 
as Captopril leads to the inhibition of a key enzyme in the formation of Ang II called 
ACE. This leads to a reduction of Ang I being converted to Ang II. With less Ang II 
circulating in the blood there is a reduction in lipogenesis (Jones, Standridge, & 
Moustaid, 1997). Therefore the animals gain less weight and also lower their BP. This 
was observed in the present study with the administration of Buchu water causing both 
a reduction in lipogenesis and lowering the BP of the HFD groups. A study done in 
1999 by de Kloet et al. corresponds with this. An ACEI was given to rats to protect 
against diet-induced obesity and glucose intolerance (de Kloet et al., 2009). Also, 
ACE-knockout mice have reduced body adiposity and increased energy expenditure 
(Jayasooriya et al., 2008). It will be important in future to measure the ACE activity of 
Buchu water. 
Kidneys in obese subjects are said to be completely encapsulated with adipose tissue. 
This protective encasing leads to a pathophysiological condition where all the excess 
visceral fat accumulates and surrounds the kidneys causing renal compression (Hall 
et al., 2003). Long term renal compression raises arterial pressure in proportion to the 
force on the kidneys (Hall et al., 1998; Hall et al., 2003). The decrease in visceral 
adipose tissue could also result in removing the renal compression that may have 
been exerted on the kidneys. However this is unlikely since we observed a reduction 
within two weeks with the onset of Buchu water treatment in the HFD group (Figure 3-
26 & Figure 3-27). Hemodynamic alterations such as increased vascular volume and 
cardiac output could also result in higher BP. All three of these alterations contribute 
to increase BP and it seems that Buchu water treatment interacted with them 
alleviating the effect and resulting in a reduction in BP. 
ALDOSTERONE 
Sustained HTN only occurs when the relationship between arterial pressure and 
natriuresis are disturbed. Under normal physiological conditions, there is a close 
relationship between these two factors. With increased pressure, there is increased 
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excretion of sodium in the urine and as a result the BP is lowered. Certain hormones 
can alter this pressure-natriuresis relationship in the kidneys. One example of this is 
the action of ALD, the primary salt-retaining hormone in the body (Laragh & Stoerk, 
1957). The actions of ALD lead to an increase in extra-cellular osmolarity and water 
retention due to the action of ALD in the nephron to reabsorb Na+ ions back into the 
blood. Aldosterone is a mineralocorticoid produced by the outer section of the adrenal 
cortex in the adrenal gland and secreted into the blood on stimulation by Ang II.  
In the present study we observed elevated ALD levels in the plasma analysed from 
the untreated HFD group (Figure 3-22). This suggests that the high levels of ALD led 
to the reabsorption of ions and water in the kidneys, therefore conservation of sodium, 
excretion of potassium, retaining of water and thus increased the BP. This is supported 
in the current study by evidence of water retention in the HFD animals as indicated by 
the low amount of urine output that was measured over a time period of 24 hours when 
the rats were placed in metabolic cages (Figure 3-24 & Figure 3-25). The Buchu 
treated HFD group had significant lower levels of plasma ALD, accompanied by the 
reduction in BP observed between the two HFD groups (Figure 3-22). However with a 
reduction in plasma ALD level you would also expect to see less water retention due 
to a reduced amount of sodium being reabsorbed in the collecting ducts of the 
nephron, resulting in a higher urine output and lower BP. On the contrary, we observed 
a reduction in BP with the treatment of Buchu water in the HFD group but no increase 
in urine production (Figure 3-24 & Figure 3-25), while a clear diuretic effect was 
observed in the control animals ingesting Buchu water (Figure 3-24 & Figure 3-25) 
although this specific group tended to drink less (Figure 3-23). In future, analysis of 
the urine of the animals may shed some light on this observation.  Alternatively, a role 
for ALD in the actions of Buchu water may be dissected out by using an ALD 
antagonist like Spironolactone (Chapman et al., 2007). 
AORTA RINGS 
In view of the very pronounced effect of the Buchu water treatment on the development 
of HTN in the animals, we investigated the possible interaction of Buchu water with 
the vascular bed to discern any effects on the vasodilatory response. The endothelium 
plays an important role in maintaining vascular tone and structure. Cardiovascular 
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disease risk states such as obesity and HTN have been showed to be associated with 
impaired endothelial function. Endothelial dysfunction is believed to be associated with 
the production of excess ROS. Reactive oxygen species react with NO that is 
produced in the endothelium, lowering the bio-availability of NO thereby diminishing 
endothelium-dependent vasodilation leading to the onset of HTN in obese individuals.  
As was showed in the results section, we could not detect that Buchu had any effect 
on the endothelium using this model (Figure 3-28). To corroborate this observation, 
we investigated some of the known proteins involved in the synthesis of NO, a potent 
vasodilator that might play a role in the reduction of BP that we observed after chronic 
Buchu water treatment for 16 weeks. Nitric oxide is predominantly produced by eNOS. 
Various protein kinases such as AMPK and PKB/Akt are known to phosphorylate and 
activate eNOS to produce NO from L-arginine. However when we measured the 
expression of PKB/Akt (Figure 3-29) and AMPK proteins (Figure 3-30 & Figure 3-31) 
involved in the activation of eNOS we found no significant difference between the 
control or HFD groups. The high fat diet resulted in reduced expression of eNOS, 
however, there was no difference found in the expression of eNOS in the in the aortas 
between the untreated or treated animals (Figure 3-32). Despite this lower expression 
of eNOS, we detected no difference in the relaxation profiles of the smooth muscle of 
the aortas in our experimental set up. The results confirm however, that Buchu water 
does not elicit a response through the vascular bed or the proteins present in it to 
reduce BP. It would be interesting to isolate the endothelial cells from the HFD animals 
to investigate whether the lower eNOS expression is reflected in them as all the other 
cell types in the aortic tissue also express eNOS. In isolated cells, the activation of 
eNOS can directly be tested on the level of NO production.  
CHAPTER 6: DISCUSSION PART 2 – Obese, insulin resistant animals without 
elevated blood pressure 
For this first part of the present study we specifically used a HFD model to induce HTN 
in the animals. In the second part of the study we made use of a different model. The 
reason for this was that we did not want these animals to develop HTN. Hypertension 
is known to cause structural and functional cardiac adaptations, such as diastolic 
dysfunction, LVH or congestive heart failure (CHF). Left ventricular hypertrophy is the 
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primary cardiac manifestation of HTN (Ganau et al., 1992; Maron et al., 1978; Messerli 
& Aepfelbacher, 1995; Verdecchia et al., 1995). Left ventricular hypertrophy has also 
been shown to affect the substrate metabolism of the cardiomyocytes (de las Fuentes 
et al., 2003; Massie et al., 1995). We therefore used this model to investigate the 
effects of Buchu water on the cardiovascular system in obese non-hypertensive 
animals. For this we made use of a well-established rat model of hyperphagia-induced 
central obesity (DIO) (Pickavance et al., 1999).  
 
6.1 Buchu water treatment and diet induced systemic alterations 
The present study indicated that Buchu water treatment does have an effect on body 
weight regulation in overweight animals. After 16 weeks of treatment rats that received 
Buchu water had a lower body weight when compared to their respective untreated 
control and DIO groups (Figure 4-33). This is consistent with the first part of the study 
since the HTN obese animals that were on the HFD and were treated with Buchu water 
for 16 weeks also had a significant reduction in weight gain (Figure 3-8) and visceral 
fat gain (Figure 3-10). 
The underlying mechanism of how Buchu water affects energy storage and leads to 
less weight gain is still unclear and is a topic of future studies. However, we have 
argued that it may work in a similar manner as other antihypertensive medication 
(ACEIs or ARB’s) that interferes with the RAAS in the body (Shimabukuro et al., 2007; 
Weisinger et al., 2009), that seems to effect the fat stores (Figure 3-10) and at the 
same time cause a reduction in BP (Figure 3-26 & Figure 3-27). 
 
6.2 Effect of Buchu water on the cardiovascular system in DIO rats 
A study done by Huisamen et al. (unpublished results) clearly demonstrated that 
Buchu water treatment was responsible for a reduction in the infarct size in ex vivo 
perfused DIO rat hearts after myocardial ischaemia followed by reperfusion (Figure 4-
35).  Diet induced obese rats have previously been shown in our lab to develop larger 
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infarct sizes after they were subjected to regional ischaemia followed by reperfusion 
(Huisamen et al., 2011). This reduction in infarct size is a clear indication of the 
cardioprotective effects of Buchu water treatment in the DIO model. Reducing the 
infarct size is the golden standard to prove cardioprotection of a substance (Lochner 
et al., 2003). After we observed these cardioprotective effects as well as a reduction 
in both the body weight and intraperitoneal fat depots in the animals ingesting Buchu 
water, we aimed to investigate whether Buchu water has any effects on the insulin 
sensitivity of glucose uptake of cardiomyocytes, as this would be a further indication 
of cardioprotection.   
Myocardial glucose uptake plays a critical role in cell survival during oxygen deprived 
states such as ischaemia, in the heart. The family of transporters responsible to 
facilitate the uptake of myocardial glucose is glucose transporters (GLUT’s). The most 
abundant glucose transporter in the heart is the GLUT-4 transporter followed by 
GLUT-1. In cardiomyocytes these two GLUT transporters account for 70% and 30% 
respectively, of total glucose carriers (Garvey, Huecksteadt, & Birnbaum, 1989).  
GLUT-1 is mainly localised in the plasma membrane and responsible for basal glucose 
uptake whereas GLUT-4 is more abundant in intracellular vesicles under basal, 
unstimulated conditions (Zorzano et al., 1996). With elevation of insulin levels or during 
ischaemic conditions, GLUT-4 translocates to the plasma membrane to enable higher 
levels of glucose uptake (Slot et al., 1991; Sun et al., 1994). Thus GLUT-4 improves 
the ability to utilize the available glucose during oxygen deprived states to supply the 
heart with ATP, produced by glycolysis.   
Our results showed that at the basal level, more radio-labelled deoxyglucose 
accumulated in cardiomyocytes prepared from the hearts of animals that consumed 
Buchu water (Figure 4-36). This may explain the cardioprotective effect observed 
resulting in smaller damage and smaller infarct development. However, we could not 
find evidence that Buchu water treatment improved insulin sensitivity in either the 
control or DIO groups. According to our results, cardiomyocytes isolated from the DIO 
animals were also not insulin resistant when compared to cells prepared from control 
animals (Figure 4-36). These results underscore those obtained in the HFD animals 
where neither the HFD nor Buchu water showed any effect on whole-body glucose 
homeostasis, as indicated by the IPGTTs (Figure 3-15). 
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Limitations of this study 
In the current study only male Wistar rats were used. The use of female rats together 
with males may have given a more clear indication of how Buchu water may have 
affected HTN. The BP together with hormones (oestrogen and progesterone) 
fluctuating during the oestrous cycle should give interesting data also on gender 
differences in the development of HTN. Another limitation is that we did not use any 
other antihypertensive drugs, such as ARBs or ACEIs as a positive control treatment. 
This could have given a better indication of how effective Buchu water was in treating 
BP when compared to commercially available drugs on the market.  
A different animal model can be used to cause systemic inflammation in the animals 
and then determine if Buchu water has any anti-inflammatory properties.  
With regards to the aorta rings, Buchu water could have been added into the organ 
bath to investigate if it elicits any response during the experimental protocol when 
administered directly to the preparation. Alternatively, endothelial cells could be 
harvested from the aortas, cultured and their ability to produce NO determined. 
In the current study, we did not determine the anti-oxidant status of the animals or any 
effects of Buchu water on that. 
 
Future studies 
 A new set of animals can be first exposed to a HFD and then treated from 
week 8 to determine the metabolic effects or corrections of Buchu water on 
the physiology of the body.  
 The interactions between Buchu water, leptin and adiponectin should receive 
further attention for future research.  
 Fasting insulin levels observed in the current study warrants further 
investigation since the current values unfortunately had a very large standard 
error.  
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 A model with a clear inflammatory response may be used to investigate 
whether Buchu treatment will have systemic anti-inflammatory effects.  
 The kidney of each individual rat was also stored in formaldehyde. This could 
be used for histological studies in the future to shed some light on the effect of 
Buchu water on the kidney function.  
 The urine collected from the animals could also be analysed to determine the 
functionality of the kidneys by measuring the amount of protein, salts and 
hormones which are excreted. This could help detect hormonal disorders 
caused by the excess adipose tissue observed in the current study.  
 The fat depots of the animals need to be analysed to investigate the 
mechanism of how Buchu water affects energy storage and leads to less 
weight gain.  
 
  




Buchu water is an affordable, already available herbal remedy and can be purchased 
without a prescription in South Africa. It therefore has enormous therapeutic potential 
in our society where inactivity is on the increase together with an unhealthy lifestyle 
which leads to high prevalence of obesity and HTN. In the current study, we have 
gathered substantial evidence of the antihypertensive properties Buchu. With regards 
to the possible mechanism involved, we have shown that: 
i) Buchu did not act as a diuretic in the animals on the HFD. The animals 
consuming Buchu water still presented with water retention 
ii) Although leptin levels were reduced by ingestion of Buchu water, this is 
probably a consequence of smaller fat depots as there were no differences 
in food intake.  
iii) There were no detectable differences in the smooth muscle contractility of 
the vascular bed, therefore an effect on vasodilation could not be 
responsible for the alleviation of hypertension 
iv) Aldosterone may play a role in the effects elicited by Buchu ingestion but 
this has not been proved conclusively 
v) Buchu may have ACEI actions as this may result in both weight loss and a 
lowering of BP as well as being cardioprotective.   
To conclude, the results from this study is novel and demonstrates that Buchu water 
do possess some antihypertensive properties. Therefore Buchu water can reduce and 
treat both the haemodynamic and metabolic aberrations seen in individuals on a HFD, 
such as HTN and glucose intolerance at least partly through visceral fat remodelling. 
Therefore we conclude that Buchu water is an alternative, cost effective and readily 
available means to treat HTN and is beneficial to one’s health. In addition, we have 
not observed any detrimental effects. 
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